

=> d his

(FILE 'HOME' ENTERED AT 15:30:28 ON 03 NOV 2007)

FILE 'REGISTRY' ENTERED AT 15:30:33 ON 03 NOV 2007

L1 SCREEN 1838 AND 1087
L2 STRUCTURE UPLOADED
L3 STRUCTURE UPLOADED
L4 STRUCTURE UPLOADED
L5 STRUCTURE UPLOADED
L6 0 S (L1 AND L2) SAM
L7 0 S (L1 AND L3) SAM
L8 0 S (L1 AND L4) SAM
L9 3 S (L1 AND L5) SAM
L10 0 S (L1 AND L2) SSS FULL
L11 1 S (L1 AND L3) SSS FULL
L12 7 S (L1 AND L4) SSS FULL
L13 183 S (L1 AND L5) SSS FULL
L14 190 S L10 OR L11 OR L12 OR L13

FILE 'CAPLUS' ENTERED AT 15:33:08 ON 03 NOV 2007

L15 296 S L14

FILE 'REGISTRY' ENTERED AT 15:33:15 ON 03 NOV 2007
SAV TEM L14 ELE537824/A

FILE 'STNGUIDE' ENTERED AT 15:34:54 ON 03 NOV 2007

FILE 'REGISTRY' ENTERED AT 15:36:08 ON 03 NOV 2007

L16 STRUCTURE UPLOADED
L17 5 S L16 SAM SUB=L14
L18 85 S L16 SSS FULL SUB=L14

FILE 'CAPLUS' ENTERED AT 15:36:49 ON 03 NOV 2007

L19 208 S L18
L20 1 S US200!-537824/APPS
L21 207 S L19 NOT L20

FILE 'REGISTRY' ENTERED AT 15:37:26 ON 03 NOV 2007
SAV TEM L18 NAR537824/A

FILE 'CAPLUS' ENTERED AT 15:38:30 ON 03 NOV 2007

FILE 'REGISTRY' ENTERED AT 15:38:52 ON 03 NOV 2007

FILE 'STNGUIDE' ENTERED AT 15:39:34 ON 03 NOV 2007

FILE 'CAPLUS' ENTERED AT 15:39:51 ON 03 NOV 2007

FILE 'STNGUIDE' ENTERED AT 15:40:01 ON 03 NOV 2007

FILE 'REGISTRY' ENTERED AT 15:42:21 ON 03 NOV 2007

L22 STRUCTURE UPLOADED
L23 STRUCTURE UPLOADED
L24 0 S L22 SAM SUB=L14
L25 19 S L22 SSS FULL SUB=L14
L26 0 S L23 SAM SUB=L14
L27 13 S L23 SSS FULL SUB=L14
L28 32 S L25 OR L27

FILE 'CAPLUS' ENTERED AT 15:43:37 ON 03 NOV 2007


L29 163 S L28
L30 162 S L29 NOT L20

FILE 'REGISTRY' ENTERED AT 15:44:03 ON 03 NOV 2007

=> d 12

L2 HAS NO ANSWERS

L2 STR




Structure attributes must be viewed using STN Express query preparation.

=> d 13

L3 HAS NO ANSWERS

L3 STR




Structure attributes must be viewed using STN Express query preparation.

=> d 14


L4 HAS NO ANSWERS

L4 STR




Structure attributes must be viewed using STN Express query preparation.

=> d 15
 L5 HAS NO ANSWERS
 L5 STR



Structure attributes must be viewed using STN Express query preparation.

=> d 122
 L22 HAS NO ANSWERS
 L22 STR




Structure attributes must be viewed using STN Express query preparation.

=> d 123
 L23 HAS NO ANSWERS

L23

STR



Structure attributes must be viewed using STN Express query preparation.

FILE 'CAPLUS' ENTERED AT 15:43:37 ON 03 NOV 2007
L29 163 S L28
L30 162 S L29 NOT L20

FILE 'REGISTRY' ENTERED AT 15:44:03 ON 03 NOV 2007

FILE 'STNGUIDE' ENTERED AT 15:45:00 ON 03 NOV 2007

FILE 'CAPLUS' ENTERED AT 15:46:14 ON 03 NOV 2007

=> s l30 and (method or pharma? or composition or treatment or medicament or disease)

3542142 METHOD
1416321 METHODS
4559136 METHOD
 (METHOD OR METHODS)
628669 PHARMA?
706365 COMPOSITION
323247 COMPOSITIONS
1022238 COMPOSITION
 (COMPOSITION OR COMPOSITIONS)
1497406 COMPN
603867 COMPNS
1833701 COMPN
 (COMPONENT OR COMPONENTS)
2307904 COMPOSITION
 (COMPOSITION OR COMPONENT)
2350482 TREATMENT
219539 TREATMENTS
2466331 TREATMENT
 (TREATMENT OR TREATMENTS)
5888 MEDICAMENT
5233 MEDICAMENTS
10381 MEDICAMENT
 (MEDICAMENT OR MEDICAMENTS)
1003889 DISEASE
272598 DISEASES
1125534 DISEASE
 (DISEASE OR DISEASES)

L31 60 L30 AND (METHOD OR PHARMA? OR COMPOSITION OR TREATMENT OR MEDICAMENT OR DISEASE)

FILE 'REGISTRY' ENTERED AT 15:53:09 ON 03 NOV 2007


L32 STRUCTURE UPLOADED
L33 0 S L32
L34 SCREEN 1838 AND 1087
L35 SCREEN 1838
L36 0 S (L35 AND L32) SAM
L37 2 S (L35 AND L32) SSS FULL
L38 0 S (L34 AND L32) SAM
L39 3 S (L34 AND L32) SSS FULL

FILE 'CAPLUS' ENTERED AT 15:55:27 ON 03 NOV 2007



L40 5 S L39
L41 1 S US200!-537824/APPS
L42 4 S L40 NOT L41

FILE 'REGISTRY' ENTERED AT 15:55:51 ON 03 NOV 2007

=> d 132
L32 HAS NO ANSWERS
L32 STR



Structure attributes must be viewed using STN Express query preparation.



chain nodes :

7 8 9 10 11 12 13 15

ring nodes :

1 2 3 4 5 6

chain bonds :

4-15 5-7 7-8 8-9 8-10 11-13 11-12 11-15

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

4-15 11-13 11-12 11-15

exact bonds :

5-7 7-8 8-9 8-10

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

Connectivity :

12:1 E exact RC ring/chain 15:2 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 15:CLASS

Generic attributes :



12:

Saturation : Saturated

15:

Saturation

: Saturated





chain nodes :
7 8 9 10 11 12 13 15
ring nodes :
1 2 3 4 5 6
chain bonds :
4-15 6-7 7-8 8-9 8-10 11-13 11-12 11-15
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
4-15 11-13 11-12 11-15
exact bonds :
6-7 7-8 8-9 8-10
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

Connectivity :
12:1 E exact RC ring/chain 15:2 E exact RC ring/chain
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 15:CLASS
Generic attributes :
12:
Saturation : Saturated
15:

Saturation

: Saturated



chain nodes :

7 8 9 10 11 12 13 15

ring nodes :

1 2 3 4 5 6

chain bonds :

1-7 4-15 7-8 8-9 8-10 11-13 11-12 11-15

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

4-15 11-13 11-12 11-15

exact bonds :

1-7 7-8 8-9 8-10

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

Connectivity :

12:1 E exact RC ring/chain 15:2 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 15:CLASS

Generic attributes :



12:

Saturation : Saturated

15:

Saturation

: Saturated





```

chain nodes :
  7  8  9  11  12
ring nodes :
  1  2  3  4  5  6
chain bonds :
  4-11  7-9  7-8  7-11
ring bonds :
  1-2  1-6  2-3  3-4  4-5  5-6
exact/norm bonds :
  7-9
exact bonds :
  4-11  7-8  7-11
normalized bonds :
  1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
  containing 1 :
  
```

```

Connectivity :
  12:1 E exact RC ring/chain
Match level :
  1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  11:CLASS
  12:CLASS 14:Atom
Generic attributes :
  12:
  Saturation      : Saturated
  
```



chain nodes :

1 2 3

chain bonds :

1-2 1-3

exact bonds :

1-2 1-3

Connectivity :

1:2 E exact RC ring/chain

Match level :

1:Atom 2:CLASS 3:CLASS

Generic attributes :

1:

Saturation : Unsaturated



Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

Element Count :

Node 1: Limited

C,C6



chain nodes :

1 4 5 6

chain bonds :

1-4 1-5 1-6

exact/norm bonds :

1-4 1-5 1-6

Connectivity :

1:3 E exact RC ring/chain 6:1 E exact RC ring/chain

Match level :

1:Atom 4:CLASS 5:CLASS 6:CLASS

Generic attributes :

1:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic



6:

Saturation : Saturated

Element Count :

Node 1: Limited

C,C6



chain nodes :

1 3 4 5 6 7 8 9 10 11

chain bonds :

1-3 1-7 3-4 4-5 4-6 7-8 7-11 8-9 8-10

exact/norm bonds :

8-10

exact bonds :

1-3 1-7 3-4 4-5 4-6 7-8 7-11 8-9

Connectivity :

1:2 E exact RC ring/chain

Match level :

1:Atom 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS

Generic attributes :

1:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

L41 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:515465 CAPLUS
 DN 141:54204
 TI Preparation of chiral aryl ketones in the treatment of
 neutrophil-dependent inflammatory diseases
 IN Allegretti, Marcello; Bertini, Riccardo; Cesta, Maria Candida; Bizzarri,
 Cinzia; Colotta, Francesco
 PA Dompe S.P.A., Italy
 SO PCT Int. Appl., 33 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2004052830	A1	20040624	WO 2003-EP13946	20031209	
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
	RW:			BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	CA 2507765	A1	20040624	CA 2003-2507765	20031209	
	AU 2003289993	A1	20040630	AU 2003-289993	20031209	
	EP 1581474	A1	20051005	EP 2003-782344	20031209	
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK		
	CN 1732145	A	20060208	CN 2003-80107685	20031209	
	JP 2006509022	T	20060316	JP 2004-558041	20031209	
	NO 2005003086	A	20050623	NO 2005-3086	20050623	
	US 2006247297	A1	20061102	US 2006-537824	20060208 <--	
PRAI	EP 2002-27453	A	20021210			
	WO 2003-EP13946	W	20031209			

OS MARPAT 141:54204

AB (R,S)-1-arylethyl ketone compds. of formula ArCH(Me)COCH(Ra)Rb and their single (R) and (S) enantiomers [wherein Ar = aryl; Ra, Rb = H, linear or branched C1-6 alkyl, Ph, α - or β -naphthyl, 2-, 3-, or 4-pyridyl, C1-4-alkylphenyl, C1-4 alkyl(α - or β -naphthyl), C1-4 alkyl(2-, 3-, or 4-pyridyl), cyano, carboxamide, CO₂H or its esters of formula CO₂R" (wherein R" = the residue of linear or branched C1-6 aliphatic alc.), a phosphonate of formula PO(OR")₂ (wherein R" is as defined above), a group of formula di-X-(CH₂)_n-Z (wherein X = CO, SO, SO₂; Z = H, tert-Bu, iso-Pr, CO₂R', cyano, Ph, α - or β -naphthyl, 2-, 3-, or 4-pyridyl, C3-6 cycloalkyl, NH-BOC, NH₂; n = 0 or an integer from 1 to 3; or Ra and Rb, with the carbon atom to which they are bound, form a cyclic residue 2,2-di(R')-substituted 4,6-dioxo-1,3-dioxane; wherein R' = Me or Et, or the two groups R' form a cyclohexane or cyclopentane ring]] are prepared. These compds. are useful in therapy as drugs for the treatment of diseases mediated by infiltrations of neutrophils induced by IL-8, such as psoriasis, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome (ARDS), idiopathic fibrosis, glomerulonephritis, bullous pemphigo and for the prevention and the treatment of damages caused by ischemia and reperfusion. Thus, (R)-(-)-ibuprofen (2 g, 9.69 mmol) was dissolved in 4 mL SOCl₂ and refluxed for 4 h to give, after evaporation, (R)-2-(4-Isobutylphenyl)propanoyl chloride as an oily yellow residue (2.34 g; 9.34 mmol). The oil was dissolved in dry 3 mL CH₂Cl₂ and the resulting solution was added to a solution of 2,2-dimethyl-1,3-dioxan-2,5-dione (Meldrum's acid) (1.35 g; 9.34 mmol) and pyridine (1.83 mL; 22.9 mmol) in dry CH₂Cl₂

(7.5 mL) previously cooled to 0-5° with a water/ice bath, and left for 1 h at this temperature and then for another hour at room temperature to give,


after workup, 2.69 g (R)-(+)-5-[2-(4-isobutylphenyl)propion-1-yl]-2,2-dimethyl-1,3-dioxan-4,6-dione. The latter compound was dissolved in dioxane (10 mL), treated with glacial acetic acid (0.84 mL) and H₂O (0.13 mL), and heated to the reflux temperature for 3 h to give, after cooling and evaporation of

the solvents and purification by means of flash chromatog. (R)-(-)-3-(4-isobutylphenyl)butan-2-one as a pale yellow oil (0.97 g; 4.75 mmol).

✓
J-42 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:460353 CAPLUS
DN 143:145782
TI 2-Arylpropionic CXC Chemokine Receptor 1 (CXCR1) Ligands as Novel
Noncompetitive CXCL8 Inhibitors
AU Allegretti, Marcello; Bertini, Riccardo; Cesta, Maria Candida; Bizzarri,
Cinzia; Di Bitondo, Rosa; Di Cioccio, Vito; Galliera, Emanuela; Berdini,
Valerio; Topai, Alessandra; Zampella, Giuseppe; Russo, Vincenzo; Di Bello,
Nicoletta; Nano, Giuseppe; Nicolini, Luca; Locati, Massimo; Fantucci,
Piercarlo; Florio, Saverio; Colotta, Francesco
CS Dompe Research and Development, Dompe S.p.A., L'Aquila, 67100, Italy
SO Journal of Medicinal Chemistry (2005), 48(13), 4312-4331
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 143:145782
AB The CXC chemokine CXCL8/IL-8 plays a major role in the activation and
recruitment of polymorphonuclear (PMN) cells at inflammatory sites. CXCL8
activates PMNs by binding the seven-transmembrane (7-TM) G-protein-coupled
receptors CXC chemokine receptor 1 (CXCR1) and CXC chemokine receptor 2
(CXCR2). (R)-Ketoprofen (1) was previously reported to be a potent and
specific noncompetitive inhibitor of CXCL8-induced human PMNs chemotaxis.
The authors report here mol. modeling studies showing a putative
interaction site of 1 in the TM region of CXCR1. The binding model was
confirmed by alanine scanning mutagenesis and photoaffinity labeling
expts. The mol. model driven medicinal chemical optimization of 1 led to a
new class of potent and specific inhibitors of CXCL8 biol. activity.
Among these, repertaxin was selected as a clin. candidate drug for
prevention of postischemia reperfusion injury.
IT 709039-97-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(2-arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel
noncompetitive CXCL8 inhibitors)
RN 709039-97-4 CAPLUS
CN 2-Butanone, 3-[4-(2-methylpropyl)phenyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

✓
J-42 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1991:228497 CAPLUS
DN 114:228497
TI 2-(4-Isobutylphenyl)-2-butene as intermediate for ibuprofen
IN Shimizu, Isao; Matsumura, Yasuo; Uchida, Kazumichi; Tokumoto, Yuichi
PA Nippon Petrochemicals Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DT Patent
LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 03024023	A	19910201	JP 1989-160325	19890622
PRAI	JP 1989-160325		19890622		

OS CASREACT 114:228497

AB The title compound (I), useful as intermediate for ibuprofen, was prepared. Four portions of Me₃COK were successively added to a mixture of Ph₃EtP⁺ Br⁻ and THF at room temperature over 30 min, 40.5 g 4-Me₂CHCH₂C₆H₄COMe was added dropwise over 1 h, then the reaction mixture was further stirred for 2 h to give 27 g I. A mixture of I, PhI(OAc)₂, Co(OAc)₂·4H₂O, and AcOH was stirred at 25° for 4 h to give 87% 4-Me₂CHCH₂C₆H₄CHMeCOMe (II) at 99% conversion. An aqueous NaOCl solution was added dropwise to a MeOH solution

of II

at -10° over 1 h and the reaction mixture was further stirred for 5 h to give ibuprofen.


IT 64758-90-3P, 3-(4-Isobutylphenyl)-2-butanone

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and haloform reaction of, ibuprofen from)

RN 64758-90-3 CAPLUS

CN 2-Butanone, 3-[4-(2-methylpropyl)phenyl]- (9CI) (CA INDEX NAME)



✓ L42 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

RN 1978:169781 CAPLUS

DN 88:169781

TI 2-(4-Alkylphenyl)propionic acids

IN Yamada, Yoshitsugu

PA Mitsui Toatsu Chemicals, Inc., Japan

SO Jpn. Kokai Tokkyo Koho, 6 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 52108949	A	19770912	JP 1976-23080	19760305
	JP 58042851	B	19830922		
PRAI	JP 1976-23080	A	19760305		

AB RPh (R = alkyl) were treated with AcAc to give p-RC₆H₄CMe(OH)Ac (I), which were reduced to p-RC₆H₄CHMeAc (II) and oxidized to give p-RC₆H₄CHMeCO₂H (III). III are analgesics and antiinflammatory agents (no data). Thus, 0.75 mol iso-BuPh was treated with AlCl₃, and 0.058 mol AcAc to give 33.6% I (R = iso-Bu), which in PhCl was reduced by Zn-Hg and HCl 1 h at 65-70° to give 86.4% II (R = iso-Bu). This was oxidized by NaOH-Br₂ in dioxane-H₂O 2 h to give 91.7% III.


IT 64758-90-3P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and oxidation by bromine and sodium hydroxide)

RN 64758-90-3 CAPLUS

CN 2-Butanone, 3-[4-(2-methylpropyl)phenyl]- (9CI) (CA INDEX NAME)



142 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1977:601111 CAPLUS

DN 87:201111

TI 2-(4-Isobutylphenyl)propionic acid

IN Matsumura, Takumi; Tani, Katsuya

PA Daito Koeki Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 3 pp.


CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 52083426	A	19770712	JP 1975-158427	19751230
PRAI	JP 1975-158427	A	19751230		
GI					




AB Antiinflammatory (no data) title acid (I) was prepared by methylating II to III, followed by oxidation with NaOBr. Thus, 29 g II was treated with MeI and NaH in C₆H₆ to give 20 g III, which was oxidized to I with NaOBr in aqueous dioxane.

IT 64758-90-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and oxidation of)

RN 64758-90-3 CAPLUS

CN 2-Butanone, 3-[4-(2-methylpropyl)phenyl]- (9CI) (CA INDEX NAME)



ANSWER 3 OF 60 CAPLUS COPYRIGHT 2007 ACS on STN

2007:769733 CAPLUS Full-text

DN 147:343757

TI Heck reactions of α - or β -substituted enol ethers with aryl bromides catalyzed by a tetraphosphane/palladium complex-direct access to acetophenone or 1-arylpropanones derivatives

AU Battace, Ahmed; Feuerstein, Marie; Lemhadri, Mhamed; Zair, Touriya; Doucet, Henri; Santelli, Maurice

CS Laboratoire de Synthèse Organique associée au CNRS, Faculté des Sciences de Saint Jérôme, Université d'Aix-Marseille, Marseille, 13397, Fr.

SO European Journal of Organic Chemistry (2007), (19), 3122-3132
CODEN: EJOCVK; ISSN: 1434-193X

PB Wiley-VCH Verlag GmbH & Co. KGaA

DT Journal

LA English

AB *Cis,cis,cis*-1, 2,3,4-Tetrakis(diphenylphosphanyl)methyl)cyclopentane/[PdCl(C₃H₅)₂] efficiently catalyzes the Heck reaction of α - and β -substituted enol ethers with aryl bromides. The arylation of 1-phenyl-1-(trimethylsilyloxy)ethylene led directly to the 2-aryl-1-phenylethanones. Similar reaction rates were observed with electron-rich, electron-deficient or sterically congested aryl bromides. Heck reaction with benzyl isopropenyl ether gave a mixture of isomers. However, this mixture gave selectively the 1-arylpropanones after hydrolysis. Employing β -methoxystyrene, 3-ethoxyacrylonitrile or Me 3-methoxyacrylate, the regioselective α -arylation of these enol ethers was observed in all cases, but mixts. of (Z) and (E) isomers were generally obtained, which in many cases yielded a single ketone product after acid treatment. The stereoselectivity of this reaction depends on steric and electronic factors, and better stereoselectivities in favor of (Z) isomers were observed with electron-rich or sterically congested aryl bromides. Higher yields were obtained for this reaction with electron-rich or sterically congested aryl bromides than with electron-poor aryl bromides. These observations suggest that the rate-limiting step of the catalytic cycle is not the oxidative addition of the aryl bromide to the palladium complex with these substituted enol ethers.

IT 2056-86-8


RL: SM (Synthetic preparation); PREP (Preparation)

of (preparation of arylketones via palladium-tedicyp-catalyzed Heck reaction

haloarenes with (silyloxy)ethenylbenzene, benzyloxypropene, methoxystyrene or (methoxy)acrylate)

RN 2056-86-8 CAPLUS

CN 2-Propanone, 1-(4-methylphenyl)- (CA INDEX NAME)



RE.CNT 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 3 OF 60 CAPLUS COPYRIGHT 2007 ACS on STN

2006:1124432 CAPLUS Full-text

DN 145:455026

TI N-alkyl-azacycloalkyl compounds as NMDA/NR2B antagonists and their preparation, pharmaceutical compositions, and use in the treatment of various diseases

IN Layton, Mark R.; Rodzinski, Kevin J.; Kelly, Michael J., III; Sanderson, Philip E.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 88pp.

CODEN: PIXXD2

DT Patent

LA English


PAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 2006/113471 A2 20061026 WO 2006-US14139 20060414
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, ME, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, GM, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, PD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2005-672639P P 20050419

OS MARPAT 145:455026

GI



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 3 OF 60 CAPLUS COPYRIGHT 2007 ACS on STN

2006:1124432 CAPLUS Full-text

DN 145:455026

TI N-alkyl-azacycloalkyl compounds as NMDA/NR2B antagonists and their preparation, pharmaceutical compositions, and use in the treatment of various diseases

IN Layton, Mark R.; Rodzinski, Kevin J.; Kelly, Michael J., III; Sanderson, Philip E.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 88pp.

CODEN: PIXXD2

DT Patent

LA English

PAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 2006/113471 A2 20061026 WO 2006-US14139 20060414
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, ME, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, GM, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, PD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2005-672639P P 20050419

OS MARPAT 145:455026

GI



2007:61333 CAPLUS Full-text

DN 146:162998

TI Preparation of 3-aminoazetidinecarboxamides as antagonists of sensory neuron specific (SNS) sodium channels

IN Hamlyn, Richard; Callis, David; Barnshaw, Christopher Geoffrey; Finch, Harry; Huckstep, Mike; Lynch, Rosemary; Mellor, Sarah

PA Vernalis (R & D) Limited, UK

SO PCT Int. Appl., 59pp.

CODEN: PIXXD2

DT Patent

LA English


PAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 2007007057 A1 20070118 WO 2006-GB2523 20060707
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, GM, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM


PRAI GB 2005-14017 A 20050707

OS MARPAT 146:162998

GI




AB Title compds. I [wherein R1, R2 = (un)substituted Ph, heteroaryl, carbocyclyl, etc.; J = (un)substituted NH, O, or direct bond; R4, R3 = H, alkyl, alkenyl, etc.; R2 and R3 may link together to form ring] and pharmaceutically acceptable salts thereof were prepared as antagonists of sensory neuron specific (SNS) sodium channels. For instance, successive treatment of [1-[4-(trifluoromethyl)phenyl]ethyl]amine with 1,1'-carbonyl diimidazole, condensation with (asetidin-3-yl)carbamate acid tert-Bu ester (67% for two steps), deprotection with TFA (99%), and reductive alkylation with 2-methylphenylacetone (20%) gave azetidinecarboxamide II. This product showed inhibition of human Nav 1.8 stably expressed in SH-SY-5Y cells with an IC50



AB Compds. represented by formula I: and/or pharmaceutically acceptable salts, individual enantiomers and stereoisomers thereof, are effective as NMDA/NR2B antagonists useful for treating conditions such as pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, ischemic brain injury including stroke. Compds. of formula I wherein W is (un)substituted (hetero)aryl; X is absent and (un)substituted C1-4 alkoxy and (un)substituted C1-3 alkyl; A is a bond and (un)substituted C2-3 alkyl, etc.; B is (un)substituted C1 alkyl, etc.; R1 and R2 are independently H and C1-3 alkyl; R3 and R4 are independently H, OH, CN and (un)substituted C1-3 alkyl, etc.; and their pharmaceutically acceptable salts, enantiomers and stereoisomers thereof are claimed. Example compound II was prepared by alkylation of tert-Bu pyrrolidin-3-ylcarbamate with [(2-bromoethoxy)methyl]benzene; the resulting tert-Bu [1-[2-(benzyloxy)ethyl]pyrrolidin-3-yl]carbamate underwent hydrolysis to give 1-[2-(benzyloxy)ethyl]pyrrolidin-3-amine, which underwent coupling with 4-chloro-1-(tetrahydropyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidine to give compound II. All the invention compds. were evaluated for their NMDA/NR2B antagonistic activity.

IT 2056-86-8, (4-Methylphenyl)acetone
RL: RCT (Reactant), RACT (Reactant or reagent)
(starting material; preparation of N-alkyl-azacycloalkyl as NMDA/NR2B antagonists useful in treatment of diseases)
RN 2056-86-8 CAPLUS
CN 2-Propanone, 1-(4-methylphenyl)- (CA INDEX NAME)



ANSWER 3 OF 60 CAPLUS COPYRIGHT 2007 ACS on STN

2006:517172 CAPLUS Full-text


DN 145:27873

TI Preparation of pyrido[2,1-a]isoquinolines as dipeptidyl peptidase IV (DPP-IV) inhibitors.

IN Boehringer, Markus; Hunsiker, Daniel; Kuhn, Bernd; Loeffler, Bernd Michael; Ricklin, Fabienne; Wessel, Hans Peter

PA ~~Am~~tz.
 SO U.S. Pat. Appl. Publ., 41 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2006116393	A1	20060601	US 2005-288648	20051128
AU 2005311511	A1	20060608	AU 2005-311511	20051121
CA 2587524	A1	20060608	CA 2005-2587524	20051121
WO 2006058628	A2	20060608	WO 2005-EPI2436	20051121
WO 2006058628	A3	20060810		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MX, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GO, GM, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
IN 2007DN03795	A	20070824	IN 2007-DN1795	20070522
PRAI EP 2004-106191	A	20041130		
WO 2005-EPI2436	W	20051121		
OS MARPAT 145:27873				
GI				



AB Title compds. (I; R1 = H, MeO; R2 = OH, (substituted) alkoxy, amino, aminocarbonylalkoxy, etc.; R3 = H, OH, (substituted) alkoxy, aminocarbonylalkoxy, amino, etc.; R4 = substituted Ph, pyridyl), were prepared Thus, (2SR,3SR,11SR)-2-[2-amino-3-(2,5-dimethylphenyl)-10-methoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-9-yloxy]acetamide hydrochloride (preparation from 9-benzoyloxy-10-methoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one given) inhibited DPP-IV with IC50 = 0.0001 µM.

IT 18026-61-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of pyridoisquinolines as dipeptidyl peptidase inhibitors)


RN 18026-61-4 CAPLUS

CN 2-Propanone, 1-(3-methylphenyl)- (CA INDEX NAME)

(preparation of pyridazine compds. as agrochem. fungicides)

RN 2096-86-8 CAPLUS

CN 2-Propanone, 1-(4-methylphenyl)- (CA INDEX NAME)




RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 6 OF 60 CAPLUS COPYRIGHT 2007 ACS on STN
 2005:1224413 CAPLUS Full-text
 143:483127

TI Aerosol formulation for the inhalation of β-adrenoceptor agonists
 IN Aven, Michael
 PA Boehringer Ingelheim International GmbH, Germany
 SO U.S. Pat. Appl. Publ., 23 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005256115	A1	20051117	US 2005-125756	20050510
DE 102004024452	A1	20051208	DE 2004-102004024452	20040514
AU 2005244414	A1	20051124	AU 2005-244414	20050510
CA 2564379	A1	20051124	CA 2005-2564379	20050510
WO 2005110421	A2	20051124	WO 2005-EP5028	20050510
WO 2005110421	A3	20060316		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GO, GM, ML, MR, NE, SN, TD, TG				
EP 1809293	A2	20070725	EP 2005-747843	20050510
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101056640	A	20071017	CN 2005-80018486	20050510
IN 2006DN06285	A	20070831	IN 2006-DN6285	20061026
NO 200605030	A	20061130	NO 2006-5030	20061102
KR 2007022084	A	20070723	KR 2006-726225	20061213
PRAI DE 2004-102004024452	A	20040514		
US 2004-578541P	P	20040610		
WO 2005-EP5028	W	20050510		
WO 2005-EP5078	W	20050511		



ANSWER 5 OF 60 CAPLUS COPYRIGHT 2007 ACS on STN
 2006:15022 CAPLUS Full-text
 144:108337

TI Preparation of pyridazine compounds as agrochemical fungicides
 IN Morishige, Hiroshi; Manabe, Akio
 PA Sumitomo Chemical Co., Ltd., Japan
 SO PCT Int. Appl., 62 pp.
 CODEN: PIXX2

DT Patent
 LA Japanese
 FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006001175	A1	20060105	WO 2005-JP10541	20050602
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GO, GM, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
JP 2006045192	A	20060216	JP 2005-158566	20050531
EP 1775290	A1	20070418	EP 2005-748513	20050602
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRAI JP 2004-189396	A	20040628		
WO 2005-JP10541	W	20050602		
OS MARPAT 144:108337				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I (R1, R2 = alkyl; R3 = halo, nitro, cyano, etc.; n = 0-5; R4 = halo, nitro, cyano, etc.; R5 = halo, nitro, cyano, etc.; n = 0-4) were prepared For example, reaction of compound II, e.g., prepared from 2,4,6-trifluorobenzaldehyde in 3 steps, with hydrazine hydrate followed by in-situ treatment with PCO2 afforded compound I. In controlling test against *Pyricularia oryzae*, 10 examples of compds. I exhibited the fungicidal activity of 20-90%.

IT 2096-86-8, (4-Methylphenyl)acetone
 RL: RCT (Reactant); RACT (Reactant or reagent)

OS CASREACT 143:483127; MARPAT 143:483127
 GI




AB The present invention relates to a propellant-free aerosol formulation of β-adrenoceptor agonists comprising one or more compds. of general formula I (R1,R2 = H, C1-4-alkyl, C1-4-alkoxy, halogen; R3 = H, C1-4-alkyl, C1-4-alkoxy, halogen, OH, O-C1-4-alkylene-CO2H, O-C1-4-alkylene-CO2-C1-4-alkyl; X = anion), optionally in the form of their tautomers, enantiomers, mixtures of enantiomers, racemates or solvates, at least one pharmaceut. acceptable acid, optionally other pharmaceut. acceptable excipients and/or complexing agents, and, as solvent, water, ethanol or their mixture For example, (R)-6-hydroxy-8-[1-hydroxy-2-(2-(4-hydroxy-2,6-dimethylphenyl)-1,1-dimethylethylamino)ethyl]-4H-benzo[1,4]oxazin-3-one-methanesulfonate (II) was prepared and formulated into aerosol inhalant containing II 10 mg, benzalkonium chloride 10 mg, citric acid 3 mg, and water 100 mL.

IT 75251-24-0
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation and aerosol formulation for inhalation of β-adrenoceptor agonists)

RN 75251-24-0 CAPLUS

CN 2-Propanone, 1-(4-ethylphenyl)- (9CI) (CA INDEX NAME)



ANSWER 7 OF 60 CAPLUS COPYRIGHT 2007 ACS on STN
 2005:1171119 CAPLUS Full-text
 143:440425

TI Preparation of benzoxazinone derivatives for treating respiratory tract diseases
 IN Bouyssou, Thierry; Konetzki, Ingo; Pestel, Sabine; Schnapp, Andreas; Hoenke, Christoph; Lustenberger, Philipp; Rudolf, Klaus; Buettner, Frank; Heine, Claude et al.
 PA Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma GmbH & Co. KG
 SO PCT Int. Appl., 54 pp.



CODEN: PIXXD2

DT Patent


LA German

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI NO 2005102350	A1	20051103	NO 2005-EP4075	20050418
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 102004019539	A1	20051110	DE 2004-102004019539	20040422
AU 2005235420	A1	20051103	AU 2005-235420	20050418
CA 2559700	A1	20051103	CA 2005-2559700	20050418
EP 1765355	A1	20070328	EP 2005-740045	20050418
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1946406	A	20070411	CN 2005-80012623	20050418
BR 2005010084	A	20071016	BR 2005-10084	20050418
US 2005272728	A1	20051208	US 2005-109030	20050419
MX 2006PA10577	A	20061110	MX 2006-PA10577	20060915
IN 2006DN05657	A	20070615	IN 2006-DN05657	20060928
NO 2006005061	A	20061107	NO 2006-5061	20061102
KR 2007054599	A	20070729	KR 2006-724543	20061122
PRAI DE 2004-102004019539	A	20040422		
US 2004-578569P	P	20040610		
WO 2005-EP4075	W	20050418		
OS MARPAT 143:440425				
GI				



EP 1761298	A1	20070509	EP 2005-739576	20050418
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101035540	A	20070912	CN 2005-80012621	20050418
BR 2005010080	A	20071016	BR 2005-10080	20050418
MX 2006PA11721	A	20061211	MX 2006-PA11721	20061010
NO 2006005060	A	20061121	NO 2006-5060	20061102
KR 2007015592	A	20070205	KR 2006-724528	20061122
PRAI DE 2004-102004019540	A	20040422		
US 2004-578542P	P	20040610		
DE 2004-102004052987	A	20041103		
EP 2005-2496	A	20050207		
WO 2005-EP4073	W	20050418		
OS MARPAT 143:416252				
GI				




AB The present invention relates to a pharmaceutical compound comprising one or more compounds of formula I wherein n denotes 1 or 2; R1 denotes hydrogen, halogen, C1-C4-alkyl or -O-C1-C4-alkyl; R2 denotes hydrogen, halogen, C1-C4-alkyl or -O-C1-C4-alkyl; R3 denotes C1-C4-alkyl, OH, halogen, -O-C1-C4-alkyl, -O-C1-C4-alkylene-COOH, -O-C1-C4-alkylene-CO-O-C1-C4-alkyl, and at least one other active substance for the treatment of respiratory diseases. The second active substance can be an anticholinergic, a phosphodiesterase IV inhibitor, a steroid, a LTD4 antagonist or an EGFR inhibitor.

IT 75251-24-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(novel medicament combinations for treatment of respiratory diseases)

RN 75251-24-0 CAPLUS

CN 2-Propanone, 1-(4-ethylphenyl)- (9CI) (CA INDEX NAME)



AB ANSWER 9 OF 60 CAPLUS COPYRIGHT 2007 ACS ON STN 1

DN 20057472128 CAPLUS Full-text

143:26597

TI Preparation of substituted pyrazoles as PPARα and PPARγ agonists for treatment of dyslipidemia


AB Title compds. I (R1 and R2 independently = H, halo, alkyl, etc.; R3 = alkyl, OH, halo, etc. with provisions) and their pharmaceutically acceptable salts, are prepared and disclosed as useful for treating respiratory tract diseases. Thus, e.g., II was prepared by coupling of 1,1-dimethyl-2-(4-methoxyphenyl)ethylamine with (6-benzoyloxy)-4H-benzo[1,4]oxazin-3-one glyoxalhydrate followed by debenzoylation. I should prove useful for the treatment of respiratory tract diseases such as but not limited to asthma, emphysema and adult respiratory distress syndrome. Pharmaceutical compds. comprising I are disclosed.

IT 75251-24-0

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzoxazinone derivs. for treating respiratory tract diseases)

RN 75251-24-0 CAPLUS

CN 2-Propanone, 1-(4-ethylphenyl)- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB ANSWER 9 OF 60 CAPLUS COPYRIGHT 2007 ACS ON STN 1

DN 20057155523 CAPLUS Full-text

143:416252

TI Novel medicament combinations for the treatment of respiratory diseases

PA Boehringer Ingelheim International GmbH, Germany

SO U.S. Pat. Appl. Publ., 50 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005239778	A1	20051027	US 2005-109094	20050419
DE 102004019540	A1	20051110	DE 2004-102004019540	20040422
DE 102004052987	A1	20060504	DE 2004-102004052987	20041103
AU 2005235419	A1	20051103	AU 2005-235419	20050418
CA 2559699	A1	20051103	CA 2005-2559699	20050418
WO 2005102349	A1	20051103	WO 2005-EP4073	20050418
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RN: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

IN Faucher, Nicolas Eric; Martres, Paul
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 176 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005049578	A1	20050602	WO 2004-EP12965	20041115
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RN: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1685113	A1	20060802	EP 2004-818779	20041115
R: AT, BE, BG, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
JP 2007511485	T	20070510	JP 2006-538823	20041115
PRAI GB 2003-26747	A	20031117		
GB 2003-29462	A	20031219		
WO 2004-EPI2965	W	20041115		
OS MARPAT 143:26597				
GI				




AB Title compds. I (p, q = 0-1; R1-2 = H, alkyl; R3-4 = H, alkyl, alkoxy, etc.; R5 = H, alkyl, etc.; R6 = alkyl, halo, alkoxy, Ph, etc.) are prepared for instance, 2-[[4-[[[1,1-dimethylethyl]phenyl]-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl-2-methylphenyl]oxy]-2-methylpropanoic acid (II) is produced in 7 steps from p-tert-butylacetophenone, Et oxalate and methylhydrazine. II has EC50 = 0.014 μM for PPARα, 5.447 μM for PPARδ and 0.007 μM for PPARγ. I are useful in the treatment of diabetes, dyslipidemia or syndrome X.

IT RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted pyrazoles as PPARα and PPARγ agonists for treatment of dyslipidemia)

RN 81561-77-5 CAPLUS

CN 2-Propanone, 1-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)




RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

✓ L3 ANSWER 10 OF 60 CAPLUS COPYRIGHT 2007 ACS ON STN
AN 2005:371233 CAPLUS Full-text
DN 142:411351
TI Preparation of thiazole-2-carboxamide derivatives as hPPAR agonist
IN Gellibert, Françoise; Jannée, Martres, Paul
PA SmithKline Beecham Corporation, USA
SO PCT Int. Appl., 19 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005037804	A1	20050428	WO 2004-EP11386	041007
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MM, MZ, NA, SD, SE, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1680410	A1	20060719	EP 2004-790285	20041007
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2007508270	T	20070405	JP 2006-530145	20041007
US 2007167628	A1	20070719	US 2007-575530	20070104
PRAI GB 2003-23702	A	20031009		
WO 2004-EP11386	M	20041007		
OS CASREACT 142:411351				
GI				




AB Title compound I and pharmaceutically acceptable salts thereof were prepared. For example, acylation of Et 2-[(4-(aminomethyl)phenyl)oxy]-2-methylpropanoate with Et 4-methyl-5-[4-(1-methylethyl)phenyl]-1,3-thiazole-2-carboxylate, e.g., prepared from 2,4-pentanedione in 4 steps, followed by hydrolysis using NaOH afforded compound I. In hPPARα binding assays, the EC50 value of compound I was 0.008 μM. Compd. I is claimed useful for the treatment of hypercholesterolemia, heart failure, etc.

IT 7306-39-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiazole-2-carboxamide derivs. as hPPAR agonist for treatment of hypercholesterolemia, heart failure, etc.)

RN 7306-39-0 CAPLUS

CN 2-Propanone, 1-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

✓ L3 ANSWER 11 OF 60 CAPLUS COPYRIGHT 2007 ACS ON STN
AN 2004:624095 CAPLUS Full-text
DN 142:335806
TI Product class 17: hydrazones
AU Kim, S.; Yoon, J.-Y.
CS Germany
SO Science of Synthesis (2004), 27, 671-722
CODEN: SSCYJ9
PB Georg Thieme Verlag
DT Journal; General Review
LA English
AB A review. Methods for preparing hydrazones and their application to organic synthesis are reviewed.

IT 18826-61-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and application of hydrazones to organic synthesis)

RN 18826-61-4 CAPLUS

CN 2-Propanone, 1-(3-methylphenyl)- (CA INDEX NAME)



RE.CNT 188 THERE ARE 188 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

✓ L3 ANSWER 12 OF 60 CAPLUS COPYRIGHT 2007 ACS ON STN

AN 2004:580869 CAPLUS Full-text
DN 141:260346
TI Oxidative rearrangements of arylalkenes with [hydroxy(tosyloxy)iodo]benzene in 95% methanol: a general, regioselective synthesis of α-aryl ketones

AU Justik, Michael W.; Koser, Gerald F.
CS Department of Chemistry The University of Akron, Akron, OH, 44325-3601, USA

SO Tetrahedron Letters (2004), 45(32), 6159-6163
CODEN: TELEAY; ISSN: 0040-4039


PB Elsevier
DT Journal
LA English
OS CASREACT 141:260346

AB The treatment of arylalkenes with [hydroxy(tosyloxy)iodo]benzene in 95% methanol affords the corresponding α-aryl ketones. This oxidative rearrangement is general for acyclic and cyclic arylalkenes and permits regioselective syntheses of isomeric α-Ph ketone pairs. For example, oxidative rearrangement of (1-(methylethyl)butyl)benzene gave 1-phenyl-2-pentanone. The oxidative rearrangement of (1-methyl-1-butenyl)benzene gave 3-phenyl-2-pentanone.

IT 2096-86-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of α-aryl ketones by oxidative rearrangement of (alkenyl)arenes in presence of [hydroxy(tosyloxy)iodo]benzene and methanol)

RN 2096-86-8 CAPLUS

CN 2-Propanone, 1-(4-methylphenyl)- (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

✓ L3 ANSWER 13 OF 60 CAPLUS COPYRIGHT 2007 ACS ON STN
AN 2003:696896 CAPLUS Full-text
DN 139:230771
TI Preparation of thiazoles as NPY receptor antagonists
IN Mattei, Patrizio; Nidhart, Werner; Nettekoven, Matthias Heinrich; Pfelezer, Philipp; Taylor, Sven
PA F. Hoffmann-La Roche A.-G., Switz.

SO PCT Int. Appl., 130 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003072577	A1	20030904	WO 2003-EP1667	030219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2475299 A1 20030904 CA 2003-2475299 20030219
AU 2003210305 A1 20030909 AU 2003-210305 20030219
EP 1480976 A1 20041201 EP 2003-742945 20030219
EP 1480976 B1 20070919


R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

BR 2003008108 A 20041207 BR 2003-8108 20030219
CN 1639158 A 20050713 CN 2003-804823 20030219
JP 2005526732 T 20050908 JP 2003-571283 20030219
AT 373654 T 20071015 AT 2003-742945 20030219
US 2003225141 A1 20031204 US 2003-374573 20030226
US 6686381 B2 20040203

MX 2004PA08379 A 20041126 MX 2004-PA8379 20040827
PRAI EP 2002-4296 A 20020228
WO 2002-EP1667 W 20030219

OS MARPAT 139:230771


GI



AB The title compds. (I, R1 = aryl, heteroaryl; R2-R4 = H, alkyl, cycloalkyl; R5 = alkyl, cycloalkyl, aryl, heteroaryl; R6 = H, alkyl, cycloalkyl; A = CO, SO2, NR6CO, OCO, n = 2-6; m = 0-2) which can be used in the form of pharmaceutical preps. for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity, were prepared and formulated. Thus, reacting 2-methylphenacyl bromide with tert-Bu 1-(3-(dimethylaminomethyl)ethyl)imidazole-5-carboxylate (preparation I) in the presence of Et3N in EtOH afforded 77% II. Compds. I have IC50 values below 1000 nM against mNPYs. Most preferred compds. I have IC50 values below 10 nM (two examples given).

IT 51052-00-7
RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of thiazoles as NPY receptor antagonists)
 RN 51052-00-7 CAPLUS
 CN 2-Propanone, 1-(2-methylphenyl)- (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


ANSWER 10 OF 60 CAPLUS COPYRIGHT 2007 ACS ON STN
 2003:665514 CAPLUS Full-text

DN 139:377954
 TI Two novel sesquiterpenes from the roots of Taiwania cryptomerioides Hayata
 AU Kuo, Yue-Hsiung; Chyu, Chou-Feng
 CS Department of Chemistry, National Taiwan University, Taipei, Taiwan, Peop.
 Rep. China
 SO Tetrahedron Letters (2003), 44(38), 7221-7223
 CODEN: TETLEA; ISSN: 0040-4039
 PB Elsevier Science B.V.
 DT Journal
 LA English
 GI




AB Two novel 3,4-secoecadinane and 4,5-seco-8(7-6)-abeoguaiane skeletons, namely taiwaninones A (I) and B (II), together with khusinodiol and 4β,6β-dihydroxy-1α,5β(H)-guai-9-ene were isolated from the roots of Taiwania cryptomerioides. Their structures were elucidated by the spectral methods. The biotransformations of taiwaninones A and B were proposed from khusinodiol and 4β,6β-dihydroxy-1α,5β(H)-guai-9-ene, resp.
 IT 623164-77-2P, Taiwaninone B
 RL: BSU (Biological study, unclassified); NPO (Natural product occurrence); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)
 (two novel sesquiterpenes from the roots of Taiwania cryptomerioides)
 RN 623164-77-2 CAPLUS
 CN 2-Butanone, 4-[2-methyl-5-(2-methylpropyl)phenyl]- (CA INDEX NAME)

PRAI EP 2001-130882 A 2001-1227
 US 2002-321692 A1 2002-1217
 WO 2002-EP14685 W 2002-1220
 OS MARPAT 139:101038
 GI




AB Pyridoisquinolines I [R1 = alkyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, cycloalkylalkyl; R2-R4 = H, halogen, OH, (un)substituted alkyl, alkoxy, alkenyl; R5 = H, F, alkyl, aryl, R6 = H, alkyl, hydroxyalkyl; R5R6 = atoms required to complete a 5- or 6-membered carbocyclic ring; R7 = H, F, alkyl] were prepared for use as DPP-IV inhibitors in the treatment of diseases, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance. Thus, 3,4-dihydro-6,7-dimethoxyisoquinoline was cyclized with AcOCH2CH2NMe3 I- to give the pyrido[2,1-a]isoquinolinone which was converted to its oxime and reduced with NiAl to give I [R1 = Bu, R2, R3 = OMe, R4-R7 = H, II]. 2μ-11.2HCl had an IC50 for inhibition of DPP-IV of 0.52 μM.
 IT 2096-86-9, 4-Methylphenylacetone
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of pyrido[2,1-a]isoquinoline derivs. as DPP-IV inhibitors)
 RN 2096-86-8 CAPLUS
 CN 2-Propanone, 1-(4-methylphenyl)- (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 10 OF 60 CAPLUS COPYRIGHT 2007 ACS ON STN
 2002:927419 CAPLUS Full-text

DN 138:14053
 TI Preparation of oxazoles and thiazoles as activators of the hPPARα receptor
 IN Gellibert, Francoise Jeanne
 PA Glaxo Group Limited, UK
 SO PCT Int. Appl., 33 pp.
 CODEN: PIXXD2
 DT Patent
 GI



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


ANSWER 15 OF 60 CAPLUS COPYRIGHT 2007 ACS ON STN
 2003:532664 CAPLUS Full-text

DN 139:101008
 TI Preparation of pyrido[2,1-a]isoquinoline derivatives as DPP-IV inhibitors
 IN Gobbi, Luca Claudio; Luebbbers, Thomas; Mattei, Patrizio; Marquizian, Robert; Wyss, Pierre Charles
 PA F. Hoffmann-La Roche AG, Switz.
 SO PCT Int. Appl., 59 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003055881	A1	20030710	WO 2002-EP14685	20021220
M: AR, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003149071	A1	20030807	US 2002-321692	20021217
US 6727261	B2	20040427		
CA 2471262	A1	20030710	CA 2002-2471262	20021220
AU 2002360074	A1	20030715	AU 2002-360074	20021220
EP 1461337	A1	20040929	EP 2002-795262	20021220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002015396	A	20041207	BR 2002-15396	20021220
JP 2005518398	T	20050623	JP 2003-556411	20021220
CN 1639162	A	20050713	CN 2002-826360	20021220
HU 2006000068	A2	20060529	HU 2006-68	20021220
NZ 533629	A	20060831	NZ 2002-533629	20021220
RU 2297417	C2	20070420	RU 2004-123215	20021220
TW 265163	B	20061101	TW 2002-91137130	20021224
US 2004176406	A1	20040909	US 2004-800991	20040315
US 6897222	B2	20050524		
ZA 2004004926	A	20050913	ZA 2004-4926	20040622
MX 2004PA06241	A	20041101	MX 2004-PA6241	20040623
IN 2004CN01416	A	20060210	IN 2004-CN1416	20040623
NO 2004001174	A	20040726	NO 2004-3174	20040726
HK 1077069	A1	20070706	HK 2005-111787	20051221

LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002096895	A1	20021205	WO 2002-EP5886	20020529
M: AR, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2448205	A1	20021205	CA 2002-2448205	20020529
AU 2002317765	A1	20021209	AU 2002-317765	20020529
EP 1399430	A1	20040324	EP 2002-747331	20020529
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2004000043	A2	20040428	HU 2004-43	20020529
BR 2002009785	A	20040601	BR 2002-9785	20020529
JP 2004532267	T	20041021	JP 2003-500074	20020529
CN 1633421	A	20050629	CN 2002-814942	20020529
TW 245760	B	20051221	TW 2002-91111392	20020529
NZ 529754	A	20051223	NZ 2002-529754	20020529
ZA 2003009095	A	20050221	ZA 2003-9095	20031121
IN 2003KN1528	A	20060519	IN 2003-KN1528	20031124
MX 2003PA11032	A	20040319	MX 2003-PA11032	20031128
US 2005070517	A1	20050331	US 2004-478936	20040510
US 7157479	B2	20070102		
PRAI GB 2001-13231	A	20010531		
WO 2002-EP5886	W	20020529		
OS MARPAT 138:14053				
GI				



AB The title compds. [I; X1 = O, S; R1, R2 = H, alkyl; or R1 and R2 may together with the carbon atom to which they are bonded form a 3-5 membered cycloalkyl ring; R3, R4 = H, halo, Me, OMe; R5 = H, alkyl; X2 = NH, NMe, O; one of Y and Z is H, and the other is O or S; R6 = (un)substituted Ph or pyridyl (wherein the N is in position 2 or 3), with the provision that when R6 is pyridyl, the

11 is unsubstituted], were prepared. E.g., a multi-step synthesis of the acid II which showed EC50 of 5 nM against hPPAR α binding, was given.


IT 75251-24-0, 4-Ethylphenylacetone

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of thiazoles or oxazoles for the treatment of hPPAR α mediated diseases)

RN 75251-24-0 CAPLUS

CN 2-Propanone, 1-(4-ethylphenyl)- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 17 OF 60 CAPLUS COPYRIGHT 2007 ACS on STN

2001:87889 CAPLUS Full-text

DN 136:278903

TI Reactions of aldehydes with polymer-supported selenoalkylenetriphenylphosphoranes. A facile method for the synthesis of carbonyl compounds

AU Huang, Xian; Sheng, Shou-Ri

CS Xixi Campus, Department of Chemistry, Zhejiang University, Hangzhou, 310028, Peop. Rep. China

SO Tetrahedron Letters (2001), 42(51), 9035-9037

CODEN: TETLEAV; ISSN: 0040-4039

PB Elsevier Science Ltd.

DT Journal

LA English

OS CASREACT 136:278903

AB The transylation reactions of polymer-bound Se bromide with alkylenetriphenylphosphoranes Ph₃P:CHR (1) gave resin Ph₃P:CR1Se-resin (2), which is sufficiently reactive to undergo Wittig-type reactions to afford the vinyllic selenide resins R²CH:CR1Se-resin (3). Cleavage gave ketones R²CH₂CO¹ and aldehydes R²CH₂CHO under different conditions.


IT 2096-86-8

RL: SPN (Synthetic preparation); PREP (Preparation)

(reactions of aldehydes with polymer-supported selenoalkylenetriphenylphosphoranes to give carbonyl compds.)

RN 2096-86-8 CAPLUS

CN 2-Propanone, 1-(4-methylphenyl)- (CA INDEX NAME)



AB The title compds. (1); A = 5-membered heteroatom, ring containing 1-2 heteroatoms selected from O, N or S; R¹ = (un)substituted Ph, 5-7 membered heteroatom, ring containing 1-3 heteroatoms selected from O, N or S; R² = H, halo, CN, etc.; X = O, S), useful in the treatment or prophylaxis of inflammatory disease, were prepared. Thus, refluxing 3-amino-5-phenyl-2-thiophenecarboxamide with trimethylsilyl isocyanate in DMF/CH₂Cl₂ afforded II.


IT 2096-86-8, (4-Methylphenyl)acetone 7306-35-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of thiophenecarboxamides as inhibitors of the enzyme IKK-2)


RN 2096-86-8 CAPLUS

CN 2-Propanone, 1-(4-methylphenyl)- (CA INDEX NAME)



RN 7306-35-0 CAPLUS

CN 2-Propanone, 1-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 19 OF 60 CAPLUS COPYRIGHT 2007 ACS on STN

2000:775870 CAPLUS Full-text

DN 134:81972

TI Exploring the potential for allergic contact dermatitis via computed heats of reaction of haptens with protein end-groups: heats of reaction of haptens with protein end-groups by computation

AU Magee, Philip S.

CS BIOSAR Research Project, Vallejo, CA, 94591, USA

SO Quantitative Structure-Activity Relationships (2000), 19(4), 356-365

CODEN: QSARDI; ISSN: 0931-8771

PB Wiley-VCH Verlag GmbH

DT Journal

LA English

AB Unlike human sensitization in allergic contact dermatitis, the primary event in the guinea pig maximization test (GPMT) is not penetration to the viable epidermis as the skin is compromised in both the sensitization and elicitation steps. The primary event is the chemical reaction of a hapten with simple protein end-groups at the recognition site of the major histocompatibility complex, class 2 (MHC II) on the cell surface of the Langerhans cells (LC). This reaction converts a benign LC into an allergen presenting cell that a T(CD4) lymphocyte recognizes as non-self and initiates the sensitizing

RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 18 OF 60 CAPLUS COPYRIGHT 2007 ACS on STN

2001:597977 CAPLUS Full-text

DN 135:180698

TI Preparation of thiophenecarboxamides as inhibitors of the enzyme IKK-2

IN Baxter, Andrew; Brough, Stephen; Fauli, Alan; Johnstone, Craig; McInally, Thomas

PA AstraZeneca AB, Swed.

SO PCT Int. Appl., 85 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001058890	A1	20010816	WO 2001-SE248	20010207
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: CH, CM, KE, LS, MW, ME, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, ME, SN, TD, TG				
CA 2396824	A1	20010816	CA 2001-2396824	20010207
EP 1261600	A1	20021204	EP 2001-902951	20010207
EP 1261600	B1	20040506		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001008143	A	20030121	BR 2001-8143	20010207
JP 2003522766	T	20030728	JP 2001-558440	20010207
AT 266019	T	20040515	AT 2001-902951	20010207
NZ 519947	A	20040528	NZ 2001-519947	20010207
PT 1261600	T	20040831	PT 2001-902951	20010207
ES 2218376	T3	20041116	ES 2001-1902951	20010207
AU 781047	B2	20050505	AU 2001-30705	20010207
US 2002107252	A1	20020808	US 2002-868884	20020205
ZA 2002005300	A	20031002	ZA 2002-5300	20020702
NO 2002003786	A	20020923	NO 2002-3786	20020809
MX 2002PA07734	A	20021011	MX 2002-PA7734	20020809
PRAI GB 2000-1154	A	20000212		
WO 2001-SE248	M	20010207		
OS MARPAT 135:180698				
GI				



sequence in the local draining lymph node. The widely used GPMT was selected for the purpose of modeling the sensitizing reaction without the complications of penetration to the viable epidermis. The compds. selected for study represent the class of electrophilic haptens that, along with their metabolic precursors (prohaptens) comprise the majority of known contact allergens. As the whole MHC II structure has no involvement with the sensitizing reaction beyond the first few atoms of the end group, methoxide ion and thiomethoxide ion were used to model activated serine and cysteine. In addition, the GPMT has a relatively broad range of error which allows the use of AMT as an adequate method for modeling the relative heats of reaction in the rate determining step. The relative reactivity of most of the known electrophilic haptens in the simplest aliphatic and aromatic form are modeled in this study. For many of those that are sensitive to substituent effects, sets of 7-10 substituted analogs were modeled to provide excellent Hammett relations with the heats of reaction. These linear free energy relations allow prediction of ACB potential in new related haptens. As a final validation of the procedure, a set of compds. scoring non-, weak-, moderate and strong as measured in the GPMT are computed for comparison with the test results and found to be in good concordance.


IT 81561-77-5

RL: ADV (Adverse effect, including toxicity); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)

(exploring the potential for allergic contact dermatitis via computed heats of reaction of haptens with protein end-groups)

RN 81561-77-5 CAPLUS

CN 2-Propanone, 1-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 20 OF 60 CAPLUS COPYRIGHT 2007 ACS on STN

1999:717486 CAPLUS Full-text

DN 132:40969

TI Determination and estimation of water solubility and n-octanol/water partition coefficient for substituted aromatic ketone and aldehyde

AU Ding, Yanbin; Cao, Jiansheng; Wang, Liansheng

CS State Key Laboratory of Pollution Control and Resource Reuse, Department of Environmental Sciences and Engineering, Nanjing University, Nanjing, 210093, Peop. Rep. China

SO Huanjing Huaxue (1999), 18(6), 543-546

CODEN: HUHUDB; ISSN: 0254-6108

PB Kexue Chubanshe

DT Journal

LA Chinese


AB Shake-flask method was used to determine water solubility (S_w) and n-octanol/water partition coefficient (K_{ow}) for 15 substituted aromatic ketone and aldehyde. The result showed that the n-octanol/water partition coeffs. were correlated with water solubility. Mol. connectivity indexes (MCI) method has been used to established correlation equations. The estimated value were well fitted with observed.

IT 2096-86-8, 2-Propanone 1-(4-methylphenyl)

RL: PRP (Properties)

(water solubility and n-octanol/water partition coefficient of substituted aromatic ketones and aldehydes)


RN 2096-86-8 CAPLUS
CN 2-Propanone, 1-(4-methylphenyl)- (CA INDEX NAME)



ANSWER 21 OF 60 CAPLUS COPYRIGHT 2007 ACS ON STN
1995:414003 CAPLUS Full-text

DN 131:299277
TI The reaction of arylacetones with boron tribromide
AU Dupont, Romain; Cotel, Philippe
CS Laboratoire Chimie Organique Physique, Univ. Lille, Villeneuve d'Ascq, F-59655, Fr.
SO Synthesis (1999), (9), 1651-1655
CODEN: SYNTAF; ISSN: 0039-7881
PB Georg Thieme Verlag
DT Journal
LA English
OS CASREACT 131:299277
AB Treatment of arylacetones with BBr₃ gives 1,3-dimethyl-2-arylnaphthalenes in fair to good yields by a tandem aldol condensation-intramol. cyclization. This reaction is limited to the electron-rich arylacetones. In the case of (methoxyphenyl)acetones, a demethylation occurs leading to 1,3-dimethyl-2-(hydroxyphenyl)naphthols. Other cyclization may occur for (2-methoxyphenyl)acetones leading to an intramol. acetal or 5-, 6- or 7-hydroxy-2-methylbenzobifurans. In the case of 1-naphthylacetone, monobromination of the resulting phenanthrene occurs.

IT 2096-86-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(tandem aldol condensation-cyclization of arylacetones with boron bromide)
RN 2096-86-8 CAPLUS
CN 2-Propanone, 1-(4-methylphenyl)- (CA INDEX NAME)




RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 22 OF 60 CAPLUS COPYRIGHT 2007 ACS ON STN
1995:414003 CAPLUS Full-text

AB A gas chromatog. method for the simultaneous determination of methamphetamine and its metabolite amphetamine in human plasma and urine is described. The method utilizes reductive alkylation with propionaldehyde and sodium borohydride to produce N-Pr deriva., which have excellent chromatog. properties. Structural analogs of the analytes, p-methylmethamphetamine and p-methylamphetamine, are used as internal stds. The method has good precision and accuracy for concns. ranging from less than 10 ng/mL to 5000 ng/mL and has been used to measure plasma concns. as part of a pharmacokinetic/pharmacodynamic study of methamphetamine in humans.

IT 2096-86-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(methamphetamine internal anal. standard preparation)
RN 2096-86-8 CAPLUS
CN 2-Propanone, 1-(4-methylphenyl)- (CA INDEX NAME)




ANSWER 24 OF 60 CAPLUS COPYRIGHT 2007 ACS ON STN
1991:655797 CAPLUS Full-text

DN 116:5990
TI Photocyclization of α-(o-tolyl)acetophenones: triplet and 1,5-biradical reactivity
AU Wagner, Peter J.; Meador, Michael A.; Zhou, Boli; Park, Bong Ser
CS Chem. Dep., Michigan State Univ., East Lansing, MI, 48824, USA
SO Journal of the American Chemical Society (1991), 113(25), 9630-9
CODEN: JACSAT; ISSN: 0002-7863
DT Journal
LA English
OS CASREACT 116:5990

AB Several ring-substituted α-(o-tolyl)acetophenones undergo photocyclization to 2-indanol derivs. in high quantum efficiency in solution and in high chemical yield as solids. The mechanism for reaction involves triplet state 8-hydrogen atom abstraction that generates 1,5-biradicals. Quenching studies indicate that the n,π* excited triplets of these ketones react, with rate consts. >10⁹ s⁻¹. Variations in triplet reactivity are ascribed to conformational equilibrium that populate reactive and unreactive geometries to different extents. The α-aryl ring eclipses the carbonyl in the lowest energy geometry, from which the most favorable geometry for reaction can be reached by small bond rotations. α-(2,4,6-Trisopropylphenyl)acetophenone forms the relatively long lived enol as well as indanol in solvent-dependent ratios; deuterium labeling indicates that the 1,5-biradical disproportionates to form enol. This does not happen with α-mesitylacetophenone, so its 54% cyclization quantum efficiency is ascribed to an internal triplet quenching that competes with hydrogen abstraction. This internal quenching is presumed to be of the charge-transfer type and does not appear to lead directly to 1,5-biradicals. 1-Methyl-2-phenyl-2-indanol is formed from α-(o-ethylphenyl)acetophenone with a Z/E ratio of 20:1 in benzene and 2:1 in methanol. The 1,5-biradical intermediates were characterized by flash spectroscopy; they have lifetimes

AN 1997:114551 CAPLUS Full-text
DN 126:171096
TI Enamine oxidations. Selective oxidative cleavage of β,β-disubstituted enamines using alumina supported permanganate.
AU Synthesis of one-carbon demethylated carbonyl compounds from enamines
Harris, Clifford E.; Chrisman, William; Bickford, Sally A.; Lee, Lawrence Y.; Torreblanca, Antonia E.; Singaram, Bakthan
CS Department of Chemistry and Biochemistry, University of California, Santa Cruz, CA, 95064, USA
SO Tetrahedron Letters (1997), 38(6), 981-984
CODEN: TETRAY; ISSN: 0040-4039
PB Elsevier
DT Journal
LA English
OS CASREACT 126:171096
AB Treatment of β,β-disubstituted enamines with potassium permanganate supported on neutral alumina leads to a mild and selective oxidative cleavage reaction which produces ketones and formaldehydes. The ketones can be isolated in high yield and purity by a simple workup procedure. The oxidizing agent is selective and preferentially oxidizes an enamine carbon-carbon double bond in the presence of a distal carbon-carbon double bond. Other functional groups unaffected by this reagent include nitriles, secondary alcs., and alkynes allowing a wide range of potentially selective oxidns.
IT 7105-39-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(oxidative cleavage of β,β-disubstituted enamines using alumina supported permanganate)
RN 7105-39-0 CAPLUS
CN 2-Propanone, 1-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 23 OF 60 CAPLUS COPYRIGHT 2007 ACS ON STN
1995:414003 CAPLUS Full-text
DN 122:180432
TI Gas chromatographic determination of methamphetamine and its metabolite amphetamine in human plasma and urine following conversion to N-propyl derivatives
AU Jacob, Peyton III; Tisdale, Eileen Cotter; Panganiban, Kristina; Cannon, Dolores; Zabel, Karen; Mandelson, John E.; Jones, Reese T.
CS Drug Dependence Research Center, Langley Porter Psychiatric Institute, University of California, San Francisco, CA, 94143, USA
SO Journal of Chromatography, B: Biomedical Applications (1995), 664(2), 449-57
CODEN: JCBREP; ISSN: 0378-4347
PB Elsevier
DT Journal
LA English

between 15 and 45 ns, with those derived from α-(o-isopropylphenyl) ketones being twice as long-lived as those derived from α-(o-methylphenyl) ketones, and show only a small solvent dependence. Biradical lifetimes and the diastereoselectivity of cyclization are interpreted in terms of biradical intersystem crossing occurring preferentially along the reaction coordinate for cyclization, such that the two processes effectively occur concurrently. The applicability of this concept to other biradicals is discussed. Authors counsel caution in addition of Br₂ to DMF.


IT 51052-00-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 51052-00-7 CAPLUS
CN 2-Propanone, 1-(2-methylphenyl)- (CA INDEX NAME)



ANSWER 25 OF 60 CAPLUS COPYRIGHT 2007 ACS ON STN
1991:655797 CAPLUS Full-text

DN 115:255797
TI Preparation and use of catechol derivatives as medical antioxidants
IN Korkalainen, Tapio Juhani; Nissinen, Erkki Aarne Olavi; Backstrom, Reijo Johannes; Piipuri, Aino Kyllikki
FA Orion-Yhtymä Oy, Finland
SO Eur. Pat. Appl., 14 pp.
CODEN: EPXKDW
DT Patent
LA English
FAN.CNT 4


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 444899	A2	19910904	EP 1991-301587	19910227
EP 444899	A3	19921125		
EP 444899	B1	19970205		
JP 04211627	A	19920803	JP 1991-30908	19910226
JP 3157846	B2	20010416		
AT 148626	T	19970215	AT 1991-301587	19910227
HR 921250	B1	20000630	HR 1992-1250	19921112
US 5489614	A	19960206	US 1995-461752	19950605
PRAI YU 1989-21	A	19890106		
GB 1990-4348	A	19900227		
FI 1986-4875	A	19861128		
GB 1987-12437	A	19870528		
US 1987-126911	A3	19871127		
US 1988-288979	A2	19881223		
US 1990-587791	A2	19900925		
US 1991-658666	B1	19910221		
US 1994-294762	B1	19940823		
OS MARPAT 115:255797				
OI				



AB The title compds. [1; R2 = CH₃CR3R4, CH₂CHR3R4; R3 = acyl, cyclopropylcarbonyl; R4 = (un)substituted aryl, cyclopropylcarbonyl; X = halo, NO₂, cyano, CF₃, CHO, CO₂H], their physiol. acceptable salts and esters, are claimed. Also claimed are the use of the known 1 (R2 = H, substituted alkyl, alkoxy, aryl, heterocyclyl, NO₂, cyano, CHO, CO₂H, CH₃CR3R4, CH₂CHR3R4; broader definitions for R3, R4 are given; X as above) and of their physiol. acceptable salts and esters for the prophylaxis and treatment of tissue damage induced in lipid peroxidn., e.g., in heart disease, rheumatoid arthritis, cancer, etc. Thus, a solution of Me₂CHCOCH₂Ph and 3,4,5-(HO)₂(O₂N)C₆H₂CHO in Me₂CHOH was saturated by HCl(g) at 20° and stirred 4 h at room temperature to give title compound I (R2 = Me₂CHCOCH₂Ph, X = O₂N). The latter in a controlled peroxidn. test in vitro had a stoichiometric factor 3.3 vs 2.0 for Trolox and 0.7 for ascorbic acid.


IT 2056-55-1, 1-(4-Methylphenyl)-2-propanone
 RL: RCT (Reactant); RACT (Reactant or reagent)
 preparation (condensation reaction of, with (dihydroxy)nitrobenzaldehyde, in of medical antioxidants)

RN 2096-86-8 CAPLUS
 CN 2-Propanone, 1-(4-methylphenyl)- (CA INDEX NAME)




ANSWER 26 OF 60 CAPLUS COPYRIGHT 2007 ACS ON STN
 AN 1991:152965 CAPLUS Full-text
 DN 114:152965
 TI Electrosynthesis of benzylic ketones
 IN Robin, Yves; Chausard, Jacques; Troupel, Michel; Guitten, Pascale
 PA Societe Nationale des Poudres et Explosifs, Fr.
 SO Fr. Demande, 27 pp.
 CODEN: FRXBL
 DT Patent
 LA French
 FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI FR 2629474	A1	19891006	FR 1988-4254	19880331
FR 2629474	B1	19910412		



RN 64758-89-0 CAPLUS
 CN 2-Propanone, 1-(4-(2-methylpropyl)phenyl)- (9CI) (CA INDEX NAME)




ANSWER 28 OF 60 CAPLUS COPYRIGHT 2007 ACS ON STN
 AN 1990:179438 CAPLUS Full-text
 DN 112:179438
 TI Facile nucleophilic addition of methyl ketone enolates to (η⁵-pentamethylcyclopentadienyl)rhodium η⁶-p-xylene dication
 AU Fish, Richard H.; Kim, Hoon Sik; Fong, Raymond H.; Adams, Richard D.
 CS Lawrence Berkeley Lab., Univ. California, Berkeley, CA, 94720, USA
 SO Organometallics (1990), 9(4), 1327-9
 CODEN: ORGN07; ISSN: 0276-7333
 DT Journal
 LA English
 OS CASREACT 112:179438
 GI



AB The facile nucleophilic addition of Me ketone enolates of acetone, 2-butanone, and 2-pentanone to (η⁵-pentamethylcyclopentadienyl)rhodium (η⁶-p-xylene dication [(Cp⁺Rh(η⁵-1,4-Me₂C₆H₄)₂)]⁺, I) were studied by using 1,2,3,4-tetrahydroisoquinoline as the base at 25° to provide complexes II (R = Me, Et,

PRAI FR 1988-4254
 CASREACT 114:152965
 OS Benzylic ketones are electrosynthesized from mixts. of an organic acid anhydride and a benzylic hetero compound chosen from benzylic quaternary ammonium salts, benzylic phosphonium compds., quaternary benzylic phosphonium compds., benzylic thiocyanates, and esters of benzylic alcs. more easily reducible than the anhydride. The anode, consumed in electrosynthesis, is chosen from Mg, Zn, Al, or their alloys. The process is easy and avoids use of benzylic halides. Application to pharmaceutical intermediates is indicated.

IT 91561-77-5P
 RL: PREP (Preparation)
 (electrosynthesis of)
 RN 81561-77-5 CAPLUS
 CN 2-Propanone, 1-(4-(1,1-dimethylethyl)phenyl)- (9CI) (CA INDEX NAME)



ANSWER 27 OF 60 CAPLUS COPYRIGHT 2007 ACS ON STN
 AN 1990:458690 CAPLUS Full-text
 DN 113:58690
 TI Method for oxidizing unsaturated aromatic compounds
 IN Shimizu, Isao; Matsumura, Yasuo; Iwamoto, Kouichi
 PA Nippon Petrochemicals Co., Ltd., Japan
 SO Eur. Pat. Appl., 10 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 350069	A2	19900110	EP 1989-112484	19890707
EP 350069	A3	19900530		
EP 350069	B1	19930317		
R: CH, DE, FR, GB, IT, LI, SE				
JP 02131435	A	19900521	JP 1989-160324	19890622
US 4967009	A	19901030	US 1989-377183	19890707
CA 1327607	C	19840308	CA 1989-605013	19890707
PRAI JP 1988-170577	A	19880708		
JP 1988-170578	A	19880708		
JP 1988-170579	A	19880708		

OS MARPAT 113:58690
 AB R1COCH₂R3Ar (I; R1,R2,R3 = H, C1-4 alkyl, aryl; Ar = aryl) are prepared by oxidation of ArCR1:CR2R3 with an aryl iodosyl compound at -50° to 200°. MeCPh:CH₂ (3 mmol) was treated with 3 mmol PhI(OAc)₂ in 60% HOAc at 25° under N to give 26% PhCH₂COMe with 30% conversion. Also prepared were 17 addnl. I. Other oxidizing agents were 4-MeC₆H₄IO, MeC₆H₄I(OBz)₂, PhI(O₂CCH₂Cl)₂, and 4-O₂N₂C₆H₄IO.

IT 2096-86-8P, (4-Methylphenyl)acetone 64758-89-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 2096-86-8 CAPLUS
 CN 2-Propanone, 1-(4-methylphenyl)- (CA INDEX NAME)

Pr). resp. The regio- and stereochem. of these ketone enolate addition reactions of I were established by a single-crystal x-ray structural anal. of the acetone enolate addition product, complex II (R = Me), to reveal that the substituted arene ligand, a 6-β-keto-substituted 1,4-dimethylcyclohexadienyl group, was bonded η⁵ to Cp⁺Rh⁺. The acetone enolate added to the unsubstituted C position on the η⁶-p-xylene ligand of complex I by backside nucleophilic attack (exo to the Rh metal center). The scope of the reaction was briefly studied to show that only enolates of Me ketones were able to undergo this nucleophilic addition reaction to I. Complex II (R = Me) was oxidized with Jones reagent to release the 2,5-dimethylbenzyl Me ketone and provides a convenient synthetic method for this class of organic compds.


IT 53291-89-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, from oxidation of rhodium complex)
 RN 53291-89-7 CAPLUS
 CN 2-Propanone, 1-(2,5-dimethylphenyl)- (9CI) (CA INDEX NAME)



ANSWER 29 OF 60 CAPLUS COPYRIGHT 2007 ACS ON STN
 AN 1990:56295 CAPLUS Full-text
 DN 112:56295
 TI Allyl- and benzylstannanes, new reagents in terpenic synthesis
 AU Andrianone, M.; Haberie, K.; Delmond, B.
 CS Inst. Pin. Univ. Bordeaux 1, Talence, 33405, Fr.
 SO Tetrahedron (1989), 45(4), 1079-88
 CODEN: TETRA8; ISSN: 0040-4020
 DT Journal
 LA English
 OS CASREACT 112:56295


AB Terpenic allyl- and benzylstannanes are easily prepared from unsatd. terpene hydrocarbons by metalation followed by quenching with trialkyltin chloride. An isomerization of unsatd. terpenes via allyltin compds. is reported, by which (+)-α-pinene was converted into (+)-β-pinene. Regioselective acylation of allyl- and benzylstannanes with acyl halides in the presence of rhodium catalysts gave mono- and sesquiterpenoid ketones which are important in the fragrance industry. Thus, treatment of 4-(Me₂CH)C₆H₄CH₂SnMe₃ with seneciyl chloride in the presence of chlorotris(triphenylphosphine)rhodium gave 53% 4-(Me₂CH)C₆H₄CH₂COCH₂Me₂. Hydroxylation and oxidation of terpene hydrocarbons via allyl- and benzylstannanes are also reported.

IT 7306-39-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 7306-39-0 CAPLUS
 CN 2-Propanone, 1-(4-(1-methylethyl)phenyl)- (9CI) (CA INDEX NAME)



ANSWER 30 OF 60 CAPLUS COPYRIGHT 2007 ACS on STN
 1989:134801 CAPLUS Full-text
 110:134801


TI Reagents and synthetic methods. 66. Reduction of α,β -unsaturated nitro compounds with tributyltin hydride
 AU Aizpurua, J. M.; Oiarbide, M.; Palomo, C.
 CS Fac. Cienc. Quim., Univ. Pais Vasco, San Sebastian, 20080, Spain
 SO Tetrahedron Letters (1987) 28(44), 5365-6
 CODEN: TELEAY; ISSN: 0040-4039
 DT Journal
 LA English
 OS CASREACT 110:134801
 AB Reduction of $R_1C_6H_4CH=CHNO_2$ ($R = H, Me, R_1 = H, 4-Me, 4-Cl, 3-NO_2, 4-Ome, 4-cyano$) with Bu_3SnH , followed by $HF-MeOH$ work-up gave $R_1C_6H_4CH_2CH_2CH_2NO_2$. The reaction of I with Bu_3SnH , followed by $3-ClC_6H_4CO_2OH$ oxidation gave $R_1C_6H_4CH_2COR$ via stannyl nitronates.
 IT 2096-86-82
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 2096-86-8 CAPLUS
 CN 2-Propanone, 1-(4-methylphenyl)- (CA INDEX NAME)



ANSWER 31 OF 60 CAPLUS COPYRIGHT 2007 ACS on STN
 1989:94624 CAPLUS Full-text
 110:94624

TI Novel electrophilic species equivalent to α -keto cations. Reactions of O,O-diprotonated nitro olefins with benzenes yield arylmethyl ketones
 AU Okabe, Kazuaki; Ohwada, Tomohiko; Ohta, Toshiharu; Shudo, Koichi
 CS Fac. Pharm. Sci., Univ. Tokyo, Tokyo, 113, Japan
 SO Journal of Organic Chemistry (1989), 54(4), 733-4
 CODEN: JOCEAH; ISSN: 0022-3263
 DT Journal
 LA English
 OS CASREACT 110:94624
 AB The N,N-dihydroxyiminium carbenium ions formed by O,O-diprotonation of nitro olefins in a strong acid, trifluoromethanesulfonic acid (TfSA), are discrete and novel dipositively charged species. The dications formed from α -substituted nitroethylenes are reactive electrophiles to give α -arylated

AB Treatment of 4- $RC_6H_4CH_2CH_2CH_2NO_2$ ($R = H, Cl, Me, OMe, cyano$) with Me_3SiCl , followed by oxidation gave 92-99% yields 4- $RC_6H_4CH_2CH_2COMe$, via trialkylsilyl nitronates. Other nitroalkanes reacted similarly to give alkoxyketones.
 IT 2096-86-82
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 2096-86-8 CAPLUS
 CN 2-Propanone, 1-(4-methylphenyl)- (CA INDEX NAME)




ANSWER 32 OF 60 CAPLUS COPYRIGHT 2007 ACS on STN
 1987:466612 CAPLUS Full-text
 107:466612


TI An organic-electrolysis vat with a sacrificial electrode
 PA Societe Nationale des Poudres et Explosifs, Japan
 SO Jpn. Kokai Tokkyo Koho, 18 pp.
 CODEN: JKKXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62056589	A	19870312	JP 1986-208089	19860905
FR 2586710	A1	19870306	FR 1985-13188	19850905
FR 2586710	B1	19900330		
EP 219367	A1	19870422	EP 1986-401895	19860829
EP 219367	B1	19900711		
R1, AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 54472	T	19900715	AT 1986-401895	19860829
US 4686018	A	19870811	US 1986-904025	19860902
PRAI FR 1985-13188	A	19850905		
EP 1986-401895	A	19860829		


AB An organic-electrolysis vat with a sacrificial electrodes is described, including uniquely designed electrodes to keep the spacing between the electrode constant. A method for preparing a carboxylic acid, etc., ketone, or aldehyde by electrochem. reduction of an organic halide using the vat is also described.
 IT 81561-77-5P
 RL: PREP (Preparation)
 (preparation of, electrochem.)
 RN 81561-77-5 CAPLUS
 CN 2-Propanone, 1-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)




ketones in high yields. This constitutes a versatile synthetic method for the preparation of α -arylated ketones, which are difficult to synthesize by the conventional Friedel-Crafts reactions.
 IT 2096-86-82
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 2096-86-8 CAPLUS
 CN 2-Propanone, 1-(4-methylphenyl)- (CA INDEX NAME)



51052-00-7 CAPLUS
 2-Propanone, 1-(2-methylphenyl)- (CA INDEX NAME)



53291-89-7 CAPLUS
 2-Propanone, 1-(2,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




ANSWER 32 OF 60 CAPLUS COPYRIGHT 2007 ACS on STN
 1988:437287 CAPLUS Full-text
 109:437287

TI Reagents and synthetic methods. 65. The Nef reaction of trialkylsilyl nitronates promoted by m-chloroperbenzoic acid. An efficient route to α -alkoxyketones from nitroalkanes
 AU Aizpurua, J. M.; Oiarbide, M.; Palomo, C.
 CS Fac. Cienc. Quim., Univ. Pais Vasco, San Sebastian, 20080, Spain
 SO Tetrahedron Letters (1987), 28(44), 5361-4
 CODEN: TELEAY; ISSN: 0040-4039
 DT Journal
 LA English
 OS CASREACT 109:437287


ANSWER 33 OF 60 CAPLUS COPYRIGHT 2007 ACS on STN
 1987:32571 CAPLUS Full-text
 106:32571

TI 3-Phenylpropionaldehydes
 IN Maso Ortigosa, Maria Teresa
 PA Spain
 SO Span., 29 pp.
 CODEN: SPKXAD
 DT Patent
 LA Spanish
 FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ES 541016	A1	19851216	ES 1985-541016	19850307
PRAI ES 1985-541016		19850307		




AB Title compds. I (R_1 and R_2 are alkyl) were prepared. The Darzens condensation of 4- $MeC_6H_4CH_2COPr$ with $ClCH_2CO_2Me$ in PhMe containing NaOMe gave glycidate ester II, and treatment of II with KOH gave I ($R_1 = Me, R_2 = Pr$).
 IT 7306-39-0P 81561-77-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 7306-39-0 CAPLUS
 CN 2-Propanone, 1-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



81561-77-5 CAPLUS
 2-Propanone, 1-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)




LJ ANSWER 35 OF 60 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1986:207120 CAPLUS Full-text
 DN 104:207120
 TI Antimalarial drugs. 60. Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl]-1,1'-biphenyl-2-ols and N-oxides.
 AU Werbel, Leslie M.; Cook, P. Dan; Elalager, Edward F.; Hung, Jocelyn H.; Johnson, Judith L.; Kesten, Stephen J.; McNamara, Dennis J.; Ortwein, Daniel F.; Worth, Donald F.
 CS Warner-Lambert/Parke-Davis Pharm. Res., Ann Arbor, MI, 48105, USA
 SO Journal of Medicinal Chemistry (1986), 29(6), 924-39
 CODEN: JMCMAR; ISSN: 0022-2623
 DT Journal
 LA English
 OS CASREACT 104:207120
 GI




AB Title compds. I [n = 0, 1; R = (un)substituted Ph, 1-naphthyl, pyridyl; R1R2N = Et2N, adamantylamino, 1-pyrrolidinyl, etc.] were prepared from substituted 1-phenyl-2-propanones, proceeding through the 5-nitro-1,1'-biphenyl-2-ols, the corresponding amino, and acetamido derivs. II and final condensation with 4,7-dichloroquinoline or the N-oxide. In a quant. structure-activity relationship study of 40 substituted Ph analogs and their N-oxides, increasing antimalarial potency vs. Plasmodium berghei in mice was found to be correlated with decreasing size (ZMR) and electron donation (DEs) of the Ph ring substituents. A significant correlation with N-oxidation could not be demonstrated. Initial high activity against P. berghei infections in mice led to expanded studies that demonstrated in addition excellent activity against resistant strains of parasite, activity in primate models, and pharmacokinetic properties apparently allowing protection against infection for extended periods of time even after oral administration. Such properties encourage the clin. trial of a member of this class in man.
 IT 2096-56-8
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (cyclocondensation of, with nitromalonaldehyde)
 RN 2096-86-8 CAPLUS
 CN 2-Propanone, 1-(4-methylphenyl)- (CA INDEX NAME)


AB Treatment of aromatic hydrocarbons with Me2CO and Mn(OAc)3 gave arylacetones in yields from 26% with PhCl to 74% with PhOMe. Ce(IV) salts were also used successfully as promoters, but gave lower yields. The reactions were relatively free of side products except with PhMe. Isomer distributions, relative rates, and partial rate factors were determined for acetylation of PhR (R = OMe, Me, Cl, F). A Hammett plot of the log of the partial rate factors for the Mn(III) system vs. σ -const. gave a slope, ρ , of -2.4 ± 0.3 . An isotope effect kH/kD of 3.8 was observed for the Mn(III)-promoted reaction with (CD3)2CO, indicating rate-determining proton loss from Me2CO. The overall mechanism involves formation and attack of acetyl radical (I) on the aromatic hydrocarbon, followed by subsequent oxidative deprotonation of the resulting σ -radical complex. I exhibits appreciable electron-deficient character in its substitution behavior with aromatic hydrocarbons.
 IT 2096-86-8
 RL: PRP (Properties)
 (isotope effect of, in aromatic acetylations)
 RN 2096-86-8 CAPLUS
 CN 2-Propanone, 1-(4-methylphenyl)- (CA INDEX NAME)




IT 18826-61-4 CAPLUS
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 18826-61-4 CAPLUS
 CN 2-Propanone, 1-(3-methylphenyl)- (CA INDEX NAME)




RN 51052-00-7 CAPLUS
 CN 2-Propanone, 1-(2-methylphenyl)- (CA INDEX NAME)



LJ ANSWER 38 OF 60 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1982:544754 CAPLUS Full-text



LJ ANSWER 36 OF 60 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1985:45546 CAPLUS Full-text
 DN 102:45546
 TI A novel route to arylacetones via a masked α -acylcarbenium intermediate
 AU Shatzmiller, Shimon; Lidor, Ramy; Shalom, Sytan; Bahar, Eliezer
 CS Dep. Chem., Tel-Aviv Univ., Tel Aviv-Jaffa, 69978, Israel
 SO Journal of the Chemical Society, Chemical Communications (1984), (12), 795-6
 CODEN: JCCCAT; ISSN: 0022-4936
 DT Journal
 LA English
 OS CASREACT 102:45546
 AB Treatment of E- and Z-BrCH2CMe:NOMe with AgBF4 and five 1,3,4-RR1R2C6H3 (R, R2 = H, Me, OMe; R1 = H, OMe, OAc) in Cl(CH2)2Cl at 25° for 18 h in the dark gave the corresponding oxime ethers E-2,4,5-RR1R2C6H2CH2CMe:NOMe in 82-91% yield; subsequent acid hydrolysis with 1:5:5 HCl-H2O-MeOH at 65° for 10 h gave 2,4,5-RR1R2C6H2CH2CMe in 90% yield. E.g., 2,5-Me2C6H3CH2CMe was obtained from 1,4-Me2C6H4. The Ag+-induced aromatic substitution occurs via the acylcarbenium ion equiv. MeC(=O)CH2+.
 IT 53291-89-7
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 53291-89-7 CAPLUS
 CN 2-Propanone, 1-(2,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




LJ ANSWER 37 OF 60 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1984:173996 CAPLUS Full-text
 DN 100:173996
 TI Aromatic acetylation promoted by manganese(III) and cerium(IV) salts
 AU Kurz, Michael E.; Baru, Vijayalakshmi; Nguyen, P. Nhl
 CS Dep. Chem., Illinois State Univ., Normal, IL, 61761, USA
 SO Journal of Organic Chemistry (1984), 49(9), 1603-7
 CODEN: JOCEAH; ISSN: 0022-3263
 DT Journal
 LA English
 OS CASREACT 100:173996

DN 97:144754
 TI Secondary amines
 IN Ferris, Michael John
 PA Beecham Group Ltd., UK
 SO Brit. UK Pat. Appl., 14 pp.
 CODEN: BAXXDU
 DT Patent
 LA English
 PAN: CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI GB 2084577	A	19820415	GB 1981-28824	19810923
GB 2084577	B	19840502		
CA 1175851	A1	19841009	CA 1981-385953	19810915
ZA 8106567	A	19820929	ZA 1981-6567	19810922
AU 8175603	A	19820401	AU 1981-75603	19810923
AU 546104	B2	19850815		
EP 51917	A1	19820519	EP 1981-304398	19810923
EP 51917	B1	19860219		
US 4432993	R1	19840221	US 1981-305117	19810924
JP 57085303	A	19820528	JP 1981-151924	19810925
ES 505801	A1	19830201	ES 1981-505801	19810925
PRAI GB 1980-31228	A	19800926		
OS CASREACT 97:144754; MARPAT 97:144754				
GI				




AB Benzofuryethanolamines I (R, R1 = H, Me; R2 = OH, (un)substituted alkoxy, alkyl; R3 = H, OH, halogen, alkyl, alkoxy; n = 1-3) were prepared. Thus 2-formylbenzofuran was treated with Me3SiCN and reduced with LiAlH4 to give 2-(2-benzofuryl)-2-hydroxyethylamine which was treated with 4-MeC6H4CH2COMe and hydrogenated to give I (R = Me, R1 = R3 = H, R2 = Me, n = 1, II) as a mixture of diastereoisomers. II had antidiabetic activity with only a slight effect on heart rate. Other I had antidiabetic, antiinflammatory, and platelet aggregation-inhibiting activity.
 IT 1056-06-8
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with benzofuryethanolamine)
 RN 2096-86-8 CAPLUS
 CN 2-Propanone, 1-(4-methylphenyl)- (CA INDEX NAME)




10537824
 ANSWER 39 OF 60 CAPLUS COPYRIGHT 2007 ACS on STN-
 AN 1982:199276 CAPLUS Full-text
 DN 96:199276
 TI Arylethanolamine derivatives and their use in pharmaceutical compositions
 IN Ferris, Michael John
 PA Beecham Group Ltd., UK
 SO Eur. Pat. Appl., 62 pp.
 CODEN: EPXDXW
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 40000	A1	19811118	EP 1981-301606	19810413
EP 40000	B1	19831012		
R: BE, CH, DE, FR, GB, IT, NL, SE				
ZA 8102669	A	19820428	ZA 1981-2669	19810423
JP 57002245	A	19820107	JP 1981-68462	19810508
ES 502008	A1	19830101	ES 1981-502008	19810508
US 4588749	A	19860513	US 1984-606597	19840503
PRAI GB 1980-15297	A	19800508		
US 1981-257480	A1	19810423		
OS MARPAT 96:199276				
GI				




AB Ethanolamines I (R1 = H, F, Cl, Br, CF3, C1-4 alkyl; R2, R3 = H, C1-4 alkyl; R4 = C1-4 alkyl; R5 = H, C1-4 alkyl; n = 1-3; 2 = O, bond), useful as hypoglycemics, antiinflammatory agents, and anti-obesity agents and having cardiac activity and effecting energy expenditure (extensive data given), were prepared Refluxing 4-MeC6H4CH2COME with 3-ClC6H4CH(OH)CH2NH2 in C6H6 4 h, then hydrogenating the product gave diastereomeric ethanolamine II.


IT 2096-86-8 81561-61-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (condensation reaction of, with ethanolamine derivate.)
 RN 2096-86-8 CAPLUS
 CN 2-Propanone, 1-(4-methylphenyl)- (CA INDEX NAME)




RN 81561-61-7 CAPLUS
 CN 2-Propanone, 1-(2,4-dimethylphenyl)- (CA INDEX NAME)




IT 7306-39-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and condensation reaction of, with hydroxyphenethylamine)
 RN 7306-39-0 CAPLUS
 CN 2-Propanone, 1-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



IT 75251-24-0P 81561-77-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reaction of, with ethanamine derivative)
 RN 75251-24-0 CAPLUS
 CN 2-Propanone, 1-(4-ethylphenyl)- (9CI) (CA INDEX NAME)



RN 81561-77-5 CAPLUS
 CN 2-Propanone, 1-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)




10537824
 ANSWER 40 OF 60 CAPLUS COPYRIGHT 2007 ACS on STN-
 AN 1982:162341 CAPLUS Full-text
 DN 96:162341

TI Direct and retro processes of organometallic fragmentation. Part VI. Aromatization metalation as a method of synthesizing benzyl organometallic compounds containing an oxo group in the benzene ring
 AU Rozenberg, V. I.; Nikanorov, V. A.; Reutov, O. A.
 CS Inst. Elementorg. Soedin., Moscow, USSR
 SO Doklady Akademii Nauk SSSR (1981), 261(3), 637-41 [Chem.]
 CODEN: DANKAS; ISSN: 0002-3264
 DT Journal
 LA Russian
 GI



AB Treatment of PhCH2MgCl with AcCl in Et2O gave intermediate I which with HgCl2 in Et2O gave 12% 2-AcC6H4CH2HgCl. Similarly, p-MeC6H4CH2HgCl and AcCl in the presence of AlBr3 gave 25% 2,4-Ac(Me)C6H3CH2HgBr as the principal product in addition to p-MeC6H4CH2COME and 2,5-Me2C6H3COME. The mechanism of these processes were discussed.



IT 2096-86-8P
 RL: FORM (Formation, nonpreparative); PREP (Preparation)
 (formation of, in acetylation of methylbenzylmercury halides by acetyl chloride)
 RN 2096-86-8 CAPLUS
 CN 2-Propanone, 1-(4-methylphenyl)- (CA INDEX NAME)



10537824
 ANSWER 41 OF 60 CAPLUS COPYRIGHT 2007 ACS on STN-
 AN 1982:162341 CAPLUS Full-text
 DN 96:162341
 TI Secondary amines and their use in pharmaceutical


compositions
 IN Ainsworth, Anthony Trevor; Smith, David Glynn
 PA Beecham Group Ltd., UK
 SO Eur. Pat. Appl., 36 pp.
 CODEN: EPXDXW
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 40915	A1	19811202	EP 1981-301883	19810429
EP 40915	B1	19840221		
R: BE, CH, DE, FR, GB, IT, NL, SE				
CA 1181087	A1	19850115	CA 1981-377242	19810508
US 4385066	A	19830524	US 1981-263168	19810513
ZA 8103203	A	19820526	ZA 1981-3203	19810514
JP 57011949	A	19820121	JP 1981-74227	19810519
AU 8170868	A	19811126	AU 1981-70868	19810520
AU 539137	B2	19840913		
ES 502402	A1	19830201	ES 1981-502402	19810521
ES 516990	A1	19831016	ES 1982-516990	19821029
PRAI GB 1980-16890	A	19800522		
OS MARPAT 96:162341				
GI				



AB Amines I (R, R1 = H, Me; R2 = H, C1-6 alkyl, C1-6 alkoxy, halo; n = 1-3) were prepared as antiobesity agents, cardiac agents, hypoglycemics, and inflammation inhibitors. Thus, 3-(CF3)C6H4COCHO was treated with H2NCHMeCH2C6H4(CO2Me)-4 in refluxing C6H6 for 2 h and the resulting mixture was reduced by NaBH4 to give amine II as a 25:75 mixture of the RR,SS and RS,SR diastereoisomers. II at 10.5 mg/kg exhibited antiobesity activity in mice. Data are also given for the effect of I on energy expenditure in mice and for cardiac, hypoglycemic, and antiinflammatory activities of I.

IT 74733-50-9
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reductive amination of, with phenylethylamine derivative)
 RN 74733-50-9 CAPLUS
 CN Benzoic acid, 2-methyl-4-(2-oxopropyl)-, methyl ester (9CI) (CA INDEX NAME)



ANSWER 42 OF 60 CAPLUS COPYRIGHT 2007 ACS ON STN

1982:115389 CAPLUS Full-text

DN 96:115389

TI Gas-chromatographic resolution of enantiomeric secondary alcohols. Stereoselective reductive metabolism of ketones in rabbit liver cytosol

AU Gal, Joseph; DeVito, Dino; Harper, Timothy W.

CS Sch. Med., Univ. Colorado, Denver, CO, 80262, USA

SO Drug Metabolism and Disposition (1981), 9(6), 557-60

CODEN: DMDAS1; ISSN: 0090-9556

DT Journal

LA English

AB A simple and rapid procedure suitable for the determination of the enantiomeric comps. of chiral alcs. (obtained by reductive metabolism of ketones such as methadone, adriamycin, etc.) extracted from biol. media is presented. The chiral alcs. were treated with (S)-(-)-1-phenylethylisocyanate [14649-03-7] and the resulting diastereomeric urethane derivs. were resolved on flexible fused silica capillary gas-liquid-chromatog. columns. The resols. of the various carbinols were good to excellent. Alc. metabolites from rabbit liver supernatant fractions were determined with this procedure. The stereoselectivity of these redns. is presented and discussed.


IT 2096-86-8

RL: RCT (Reactant); RACT (Reactant or reagent)

(reduction of, by liver, stereoselectivity of)

RN 2096-86-8 CAPLUS

CN 2-Propanone, 1-(4-methylphenyl)- (CA INDEX NAME)



ANSWER 43 OF 60 CAPLUS COPYRIGHT 2007 ACS ON STN

1981:83945 CAPLUS Full-text

DN 94:83945

TI 5-substituted pyranone compounds for pharmaceutical uses

IN Clark, Barry Peter; Ross, William James; Todd, Alec

PA Lilly Industries Ltd., UK

SO Ger. Offen., 39 pp.


CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

CN 2-Propanone, 1-(4-butyphenyl)- (9CI) (CA INDEX NAME)



ANSWER 44 OF 60 CAPLUS COPYRIGHT 2007 ACS ON STN

1981:15372 CAPLUS Full-text

DN 94:15372

TI Secondary amines and their use in pharmaceutical preparations

IN Ainsworth, Anthony Trevor; Smith, David Glynn

PA Beecham Group Ltd., UK

SO Eur. Pat. Appl., 89 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 6735	A1	19800109	EP 1979-301197	19790621
EP 6735	B1	19800615		
R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
DK 7902727	A	19800204	DK 1979-2727	19790627
CA 1159072	A1	19811220	CA 1979-330733	19790627
AU 7948498	A	19800103	AU 1979-48498	19790628
AU 523681	B2	19820812		
JP 55009085	A	19800122	JP 1979-82545	19790628
JP 01030820	B	19890622		
ZA 7902331	A	19800730	ZA 1979-3231	19790628
ES 483746	A1	19800416	ES 1979-483746	19790830
US 4479849	A	19841023	US 1983-474199	19830310
ES 546425	A3	19860201	ES 1985-546425	19850731
US 4654371	A	19870331	US 1985-785608	19851008
US 4753962	A	19880628	US 1986-936714	19861201
PRAI GB 1978-28208		19780628		
GB 1978-42115		19781127		
US 1979-51440	A1	19790625		
US 1982-382379	A3	19820527		
US 1985-785608	A1	19851008		
OS MARPAT 94:15372				



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 3012597	A1	19801016	DE 1980-3012597	19800401
ES 490122	A1	19810401	ES 1980-490122	19800331
IL 59748	A	19831130	IL 1980-59748	19800331
DK 8001421	A	19801006	DK 1980-1421	19800401
FI 8001020	A	19801006	FI 1980-1020	19800401
SE 8002515	A	19801006	SE 1980-2515	19800401
AU 8057031	A	19801009	AU 1980-57031	19800401
AU 535315	B2	19840315		
FR 2453168	A1	19801031	FR 1980-7447	19800402
FR 2453168	B1	19830812		
ZA 8001977	A	19810729	ZA 1980-1977	19800402
AT 8001818	A	19820215	AT 1980-1818	19800402
AT 368499	B	19821011		
HU 25279	A2	19830628	HU 1980-785	19800402
HU 184257	B	19840730		
CH 646967	A5	19841228	CH 1980-2589	19800402
BE 82644	A1	19801003	BE 1980-47126	19800403
GB 2047698	A	19801203	GB 1980-11362	19800403
DD 150002	A5	19810812	DD 1980-220217	19800403
PL 123700	B1	19821130	PL 1980-223229	19800403
CA 1142944	A1	19830315	CA 1980-349145	19800403
NL 8002025	A	19801007	NL 1980-2025	19800404
JP 55133376	A	19801017	JP 1980-44550	19800404
CS 214826	B2	19820625	CS 1980-2358	19800404
SU 976850	A3	19821123	SU 1980-2905747	19800404
RO 81048	A1	19830201	RO 1980-100749	19800405
US 4364956	A	19821221	US 1981-303307	19810917
GB 2123814	A	19840208	GB 1983-12570	19830506
GB 2123814	B	19840801		
PRAI GB 1979-12063	A	19790405		
US 1980-134387	A3	19800327		
GB 1980-11362	A	19800403		
OS CASREACT 94:83945; MARPAT 94:83945				
GI				

AB The title compds. (I; R = H, alkyl, halogen; R1 = CO2R4, CONHR4, CN, 5-tetrazolyl, 5-tetrazolylcarbamoyl; R2, R4 = H, alkyl; R3 = optionally substituted Ph; Z = bond, O, S, SO, SO2) and their salts were prepared for use in treatment of allergies, especially asthma (no data). Thus, PhCH2COMe reacted with Me2NCH(OMe)2 to give Me2NCH:CPHCOMe, which was refluxed with (EtO2C)2 in EtOH-NaOEt to give I (R = R2 = H, R1 = CO2Et, R3Z = Ph).

IT 76512-42-02

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and condensation of, with DMF acetal, pyranone derivative)

RN 76512-42-0 CAPLUS

AB The title compds. I (R1 = H, F, Cl, OH, HOCH2, Me, MeO, H2N, HCONH, AcNH, MeSO2NH, O2N, PhCH2O, MeSO2CH2, H2NCONH, CF3, 4-MeOC6H4CH2NH2; R2 = H, F, Cl, HO; R3 = H, Cl, HO; R4, R5 = H, Me, Et, Pr; R6 = CO2H, CONH2, CO2R where R = alkyl; R7 = H, Et, F, Me, MeO, HO, CO2H, CONH2, CO2R), useful as antidiabetics and in treatment of obesity (no data), were prepared. Thus, 4-MeO2CC6H4CH2COMe refluxed with 4,3-HO(HOCH2)C6H4CH(OH)CH2NH2 followed by hydrogenation of the mixture gave II.


IT 74733-50-91

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction with ethanamines)

RN 74733-50-9 CAPLUS

CN Benzoic acid, 2-methyl-4-(2-oxopropyl)-, methyl ester (9CI) (CA INDEX NAME)



ANSWER 45 OF 60 CAPLUS COPYRIGHT 2007 ACS ON STN

1978:189721 CAPLUS Full-text

DN 88:189721

TI Pull-push mechanism for the 1,2-hydrogen rearrangement of carbenes.

Substituent and deuterium isotope effects for thermal decomposition of 1-phenyl-2-diazopropanes

AU Su, Dean T. T.; Thornton, Edward R.

CS Dep. Chem., Univ. Pennsylvania, Philadelphia, PA, USA

SO Journal of the American Chemical Society (1978), 100(6), 1872-5

CODEN: JACSAT; ISSN: 0002-7863

DT Journal

LA English

AB Intramol. and intermol. D isotope effects in the rearrangement of carbenes generated from p-RC6H4CH2CMe2N2 (R = Me, H, Cl) and a Hammett treatment of the competition between benzylic and terminal H migration indicated a pull-push mechanism, which can be pictured roughly as electrophilic attack on the C-H bond by the phantom p orbital of the carbene along with backside nucleophilic attack by the carbene unshared electron pair to push the H away and form the new bond. The data are consistent only with a nonzero barrier for the carbene H rearrangement.


IT 60242-83-7P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and tosylhydrazine formation from)


RN 60343-83-7 CAPLUS

CN 2-Propanone-1-(4-methylphenyl)- (9CI) (CA INDEX NAME)




ANSWER 46 OF 60 CAPLUS COPYRIGHT 2007 ACS ON STN
 AN 1976:22392 CAPLUS Full-text
 DN 88:22392
 TI 4-Substituted butan-2-ones, but-3-en-2-ones, butan-2-ols, and but-3-en-2-ols and pharmaceutical compositions containing them
 IN Cole, William Gwyn; Goudie, Alexander Crossan; Rose, Carl John
 PA Beecham Group Ltd., UK
 SO Brit., 17 pp.
 CODEN: BRXXAA
 DT Patent
 LA English
 FAN: CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI GB 1479297	A	19770713	GB 1974-29651	19740704
US 4062978	A	19771213	US 1975-588638	19750620
US 4393079	A	19830712	US 1976-750684	19761215
US 4216232	A	19800805	US 1978-878675	19780217
PRAI GB 1974-29651	A	19740704		
US 1975-588638	A3	19750620		
US 1975-599638	A3	19750620		
US 1976-750713	A1	19761215		
OS MARPAT 88:22392				
GI				




AB Nineteen title compds. I [R = 4-aryl, -acyl, -alkyl, -allyloxy, -Ph, 3-PhO, -PhCO; R1 = H, 3-F, 4-MeO; Z = (CH2)2, CHMeCH2, CH2CH; R2R3 = O; R2 = H, R3 = OH] possess potent antiinflammatory activity but do not irritate the gastrointestinal tract to any major extent at the therapeutic dose when administered orally. Fourteen I were prepared, mainly by Friedel-Crafts acylation reactions or Cu-catalyzed alkylation. The antiinflammatory activities of I (R = 4-Ph, R2R3 = O) [R1 = H, 3-F, Z = CHMeCH2; R1 = H, Z = CH2CH; (CH2)2] were assessed in the carrageenan rat paw edema test; active doses were 30-33.3 mg/kg orally.
 IT 65170-92-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (inflammation inhibitor, preparation of)
 RN 65170-92-5 CAPLUS
 CN 2-Pentanone, 1-[4-(2-methylpropyl)phenyl]- (9CI) (CA INDEX NAME)




RN 58443-84-8 CAPLUS
 CN 2-Propanone, 1-[2-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 58443-85-9 CAPLUS
 CN 2-Propanone, 1-[2-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)




ANSWER 48 OF 60 CAPLUS COPYRIGHT 2007 ACS ON STN
 AN 1974:520048 CAPLUS Full-text
 DN 81:120048
 TI New synthetic reactions. Regioselectivity and chemospecificity of the cyclopentane annulation-cyclopentenone annulation
 AU Trost, Barry M.; Kurozumi, Seizi
 CS Dep. Chem., Univ. Wisconsin, Madison, WI, USA
 SO Tetrahedron Letters (1974), (22), 1929-32
 CODEN: TETLEY; ISSN: 0040-4039
 DT Journal
 LA English
 OS CASREACT 81:120048
 GI For diagram(s), see printed CA Issue.
 AB Successive treatment of the oxaspiropentane I with LiN(CHMe2)2 in hexane and Me3SiCl followed by heating (330°) gave the cyclopentanone II. Use of Li pyrrolidide in place of LiN(CHMe2)2 gave the enol derivative III. Acid hydrolysis of III gave the cyclopentanone IV, successive bromination and dehydrobromination of III gave the cyclopentenone V.
 IT 2096-86-8
 RL: PROC (Process)
 (cycloaddn. of, with cyclopropane derivative)
 RN 2096-86-8 CAPLUS
 CN 2-Propanone, 1-(4-methylphenyl)- (CA INDEX NAME)




ANSWER 47 OF 60 CAPLUS COPYRIGHT 2007 ACS ON STN
 AN 1976:73823 CAPLUS Full-text
 DN 84:73823
 TI Synthesis of arylacetones by the SRN 1 arylation of acetone enolate ion
 AU Bunnett, Joseph F.; Sundberg, John E.
 CS Univ. California, Santa Cruz, CA, USA
 SO Chemical & Pharmaceutical Bulletin (1975), 23(11), 2620-8
 CODEN: CPBTAL; ISSN: 0009-2363
 DT Journal
 LA English
 OS CASREACT 84:73823
 AB Numerous aryl bromides and iodides react with acetone enolate ion in liquid NH3 under irradiation to form arylacetones in high yield. This synthesis is successful with bromo- or iodobenzene derivs. carrying alkoxy, alkyl, phenyl, halogen, and carboxylate substituents, and with halogen derivs. of polynuclear aromatic hydrocarbons. The method is remarkably insensitive to steric hindrance; for example, 2,4,6-triethylbromobenzene reacts quite well. With greater steric hindrance, as in 2,4,6-triisopropylbromobenzene, reactivity falls and a side reaction of dehalogenation becomes appreciable. The synthesis was unsuccessful with the diethylamino, nitro and ionized hydroxy substituents. K-stimulated reactions of a few aryl diethyl phosphates with acetone enolate ion give generally lower yields of arylation and larger yields of dephosphation (hydrocarbon) products, compared even to K-stimulated reactions with aryl bromides. It is postulated that the lesser formation of hydrocarbon products from the aryl bromides is related to transport effects and solution inhomogeneity.
 IT 58443-76-8P 58443-77-9P 58443-84-8P 58443-85-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 58443-76-8 CAPLUS
 CN 2-Propanone, 1-[2,5-bis(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 58443-77-9 CAPLUS
 CN 2-Propanone, 1-[2,5-bis(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



ANSWER 49 OF 60 CAPLUS COPYRIGHT 2007 ACS ON STN
 AN 1972:72126 CAPLUS Full-text
 DN 76:72126
 ORF 76:11609a,11612a
 TI Principle for establishing a carbon chain on an aromatic ring in place of nitrogen, oxygen, fluorine, sulfur, chlorine, bromine, or iodine functionality
 AU Rossi, Roberto A.; Bunnett, J. F.
 CS Univ. California, Santa Cruz, CA, USA
 SO Journal of the American Chemical Society (1972), 94(2), 683-4
 CODEN: JACSAT; ISSN: 0002-7863
 DT Journal
 LA English
 AB On reaction with K acetate and K metal in liquid NH3 at -78°, PhNMe3·I-, PhOP(O)(OEt)2, PhF, Ph2S, PhCl, PhBr and PhI give PhCH2Ac and PhCH2CH(OH)Me in (combined) yields of 46-89%. p-RC6H4Br and p-RC6H4NMe3·I- (R = Me, MeO) similarly give (after oxidation) p-RC6H4CH2Ac. The method is of special interest because ArNMe3· and ArOP(O)(OEt)2 (Ar = aryl) are easily made from ArNH2 and ArOH, resp.
 IT 2096-86-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 2096-86-8 CAPLUS
 CN 2-Propanone, 1-(4-methylphenyl)- (CA INDEX NAME)



ANSWER 50 OF 60 CAPLUS COPYRIGHT 2007 ACS ON STN
 AN 1968:505835 CAPLUS Full-text
 DN 69:105835
 ORF 69:19758h,19799a
 TI 1,3-Dipolar cycloadditions on activated alkenes. II. Thermolysis of 3-cyano-3-ethoxycarbonyl-1-pyrazolines
 AU Hamelin, Jack; Carrie, Robert
 CS Fac. Sci. Rennes, Rennes, Fr.
 SO Bulletin de la Societe Chimique de France (1968), (6), 2513-20
 CODEN: BSCFAS; ISSN: 0037-8968
 DT Journal
 LA French
 GI For diagram(s), see printed CA Issue.

AB I and II compds. are heated to give mixts. of Me(RCH₂)C(CN)CO₂Et (III), R₂C(CN)CO₂Et (IV), and V compds. Thus, I (R = p-MeOC₆H₄) is subjected to thermolysis to give 48% Et α-cyano-β-methyl-β-(p-methoxybenzyl)acrylate (VI), 18% Et α-cyano-β-ethyl-β-(p-methoxyphenyl)acrylate (VII), and 18% Et 2-methyl-2-(p-methoxyphenyl)-1-cyanocyclopropane (VIII). II (R = p-MeOC₆H₄) gives 78% VI, 5% VII, and 4% VIII. Also subjected to thermolysis are the following compds. (4 III, 4 IV, and 4 V obtained given): I (R = p-ClC₆H₄), 36, 42, 25; II (R = p-ClC₆H₄), 88, 2, 7; I (R = Ph), 29, 41, 0; I (R = p-tolyl), 35, 35, 19; II (R = p-tolyl), 74, 6, 7; I (R = Et), 10, 52, 38; II (R = Et), 40, 24, 36; I (R = iso-Pr), 24, 42, 34; II (R = iso-Pr), 42, 12, 26. I (R = Me), or II (R = Me), gives 65% MeEtC(CN)CO₂Et and 35% V (R = Me). N.M.R., IR, and UV data are given for the III (R = Ph, p-tolyl, p-ClC₆H₄, and p-MeOC₆H₄). The separation of VIII (b2-3 179-80°) and V (R = p-tolyl) (b2-3 169-71°) is described. Et 4-phenyl-4-benzyl-3-cyano-1-pyrazoline-3-carboxylate gives Ph(PhCH₂CH₂)C(CN)CO₂Et, m. 95°. The following p-RC₆H₄CH₂CO₂Me compds. (R and b.p./mm. given): Cl, 82-4°/2-3; MeO, 100-2°/2; and Me, 138-40°/28; and VI (b0.5 175-7°), III (R = p-ClC₆H₄) (m. 54°), III (R = p-tolyl) (b0.1 138-40°), p-MeC₆H₄CO₂Et (b2 70-2°), VII (m. 79-80°), IV (R = Ph), IV (R = p-ClC₆H₄) (m. approx. 70°), and IV (R = p-tolyl) (b2 140°) are prepared according to known methods. Half-wave potentials are given for the III and IV, (AR = Ph or a p-substituted Ph group).


IT 2096-86-8P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

RN 2096-86-8 CAPLUS

CN 2-Propanone, 1-(4-methylphenyl)- (CA INDEX NAME)



L31 ANSWER 51 OF 60 CAPLUS COPYRIGHT 2007 ACS ON STN

AN 1960-34070 CAPLUS Full-text

DN 54:34070

OREF 54:66202-d

TI A new method of preparation of o-tolylacetone

AU Konieczny, Mieczyslaw; Bobranski, Boguslaw

CS Akad. Med., Wrocław, Pol.

SO Roczniki Chemii (1959), 33, 1027-30

CODEN: ROCHAC; ISSN: 0035-7677

DT Journal

LA English

AB o-Cyanomethylbenzene (4.8 g.) in 5 g. dry EtOAc was added slowly to a boiling mixture of 4.6 g. Na butoxide in 10 ml. anhydrous BuOH. The Na salt, precipitated at low temperature, was washed with Et₂O, dissolved in H₂O, and acidified with H₂SO₄ to obtain o-(acetylcyanomethyl)-toluene (I), b2 133-5°, yield 48%. I (1.46 g.) was heated with 6.4 ml. concentrated H₂SO₄ and 6 ml. H₂O, extracted with Et₂O, dried, and distilled to yield 76% o-tolylacetone, b3.5 87°, oxime m. 79-80°, 2,4-dinitrophenylhydrazones m. 145°.

IT 2096-86-7, 2-Propanone, o-tolyl-

(and derivs.)

RN 51052-00-7 CAPLUS

m.p. at about 210°, at approx. 40% I concentration. The pure individual keto alcs. could not be isolated.


IT 2096-86-7P, 2-Propanone, p-tolyl-

RL: PREP (Preparation)

(preparation of)

RN 2096-86-8 CAPLUS

CN 2-Propanone, 1-(4-methylphenyl)- (CA INDEX NAME)



L31 ANSWER 53 OF 60 CAPLUS COPYRIGHT 2007 ACS ON STN

DN 1951:8882 CAPLUS Full-text

OREF 45:16268-1,1627a-b

TI Ketones

IN Wolf, Anton

PA Knoll A.-G. Chemische Fabriken

DT Patent

LA Unavailable

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 753228		19501003	DE 1940-K159256	19401112

GI For diagram(s), see printed CA Issue.

AB The process of preparing ketones by saponifying esters of α-alkyl-substituted β-(p-methoxyphenyl)glycidic acid in alkaline medium and splitting the resulting salts of the glycidic acid according to Ger. 727,045 is improved by use of esters of CH₂CH(CO₂R') (I), of other α-alkyl-β-arylglycidic acids as initial material and by using organic acids instead of or as well as mineral acids to split the resulting salts. The ketones are useful as intermediates for the preparation of pharmaceuticals. Examples are given of the preparation of: benzyl Me ketone, b20 102-4°, from I (R = Ph, R' = Me; R'' is not specified); benzyl Et ketone, b15 116-18°, from I (R = Ph, R' = Et); o-methoxybenzyl Me ketone, b9 135-40°, from I (R = o-MeOC₆H₄, R' = Me); o-methoxybenzyl Me ketone, b10 127-30°, from I (R = o-MeOC₆H₄, R' = Me); 3,4-dimethoxybenzyl Me ketone (?), b7 170-5°, from I (R = 3,4(MeO)₂C₆H₃, R' = iso-Pr); p-tolyl Me ketone (?), b8 108-12°, from II (R = p-MeC₆H₄, R' = Me). [The names of the last 2 compds. are apparently typographical errors for 3,4-dimethoxybenzyl iso-Pr ketone and p-methylbenzyl Me ketone, resp.-Abstractor.]

IT 2096-86-8P, 2-Propanone, p-tolyl-


RL: PREP (Preparation)

(preparation of)

RN 2096-86-8 CAPLUS

CN 2-Propanone, 1-(4-methylphenyl)- (CA INDEX NAME)

CN 2-Propanone, 1-(2-methylphenyl)- (CA INDEX NAME)



L31 ANSWER 52 OF 60 CAPLUS COPYRIGHT 2007 ACS ON STN

AN 1951:55595 CAPLUS Full-text

DN 45:55595

OREF 45:95049-1,9505a-d

TI Isomeric transformations of α-keto alcohols. VIII. Effect of a methyl group in the para position in a phenyl nucleus on the relative stability of isomeric alkaryl α-keto alcohols

AU Temnikova, T. I.; Petrova, L. A.

CS Leningrad State Univ.


SO Zhurnal Obshchei Khimii (1951), 21, 677-84

CODEN: ZOKHAA; ISSN: 0044-460X

DT Journal

LA Unavailable

AB Cf. C.A. 44, 1056d, 4442f. Introduction of Me into the para position of Ph in alkaryl α-keto alcs. changes the properties of the substances by the inductive and mesomeric effects of the Me group. Of MeC₆H₄COCH(OH)Me and MeC₆H₄CHOCHOME, the former is most stable. A saturated solution of 30 g. HCO₂K in MeOH at 40° is treated with a 50% MeOH solution of p-MeC₆H₄CHBrAc (31 g. p-MeC₆H₄CH₂Ac brominated and the crude product used directly) and stirred at gentle reflux 10 hrs. to yield 27% p-tolylacetylcarbinol (I), b1 100-1°, b1.5-2.0 103-6°, which on standing rapidly deposits a solid residue; semicarbazone, m. 189-90° (from EtOH); osazone, m. 141-3° (from EtOH). Treatment of the alc. with 2-3% MeOH-HCl yields the cyclodimethylidylactolide, C₂H₂MeO₄, m. 253°. Attempts to prepare the carbinol by heating the Br ketone in a sealed tube with HCO₂K at 110° gave tolylaceton and acetyldimethyl. Isolated as the disemicarbazone, m. 223-4° (decomposition, sealed tube). The solid m. 173°, formed on storage of the carbinol, has no OH groups, nor does it form a semicarbazone; possibly it is (p-MeC₆H₄CHAc)₂O. Heating p-MeC₆H₄COCHBrMe with HCO₂K and MeOH in a sealed tube 10 hrs. at 110° gave 37% product (II), b8 129-31°, b2 109-10°, b1 96°; semicarbazone, m. 188-9°, does not depress the m.p. of I semicarbazone; the yield of the semicarbazone indicates that the condensation yields a mixture of keto alcs. containing some 20-30% I. Treatment of the crude II with H₂NCONHNH₂ in aqueous MeOH, filtration of the precipitated semicarbazone, acidification of the filtrate with 5% H₂SO₄, warming on a steam bath, and extracting with Et₂O gave methyl-p-tolylacetylcarbinol cyclodimethylidylactolide, m. 220° (from C₆H₆-EtOH). Heating EtCl with crude II and BaCO₃ failed to yield a Br derivative, but heating 4 g. p-MeC₆H₄COCHBrMe and 4.2 g. BaO₂ in EtOH readily gave methyl-p-tolylacetylcarbinol benzoate, m. 96-9° (from ligroine). The isomerization of the 2 keto alcs. was followed by thermal analysis of their lactolides. Crude II on this basis contains 20-5% I and 75-80% p-MeC₆H₄COCH(OH)Me (III). Heating this mixture (6.4 g.) 20 hrs. to 100° with fresh BaCO₃ in a CO₂ stream gave the cyclolactolide, m. 226°, corresponding to 90-5% III. Heating substantially pure I under similar conditions gave a cyclolactolide whose m.p. (227°) indicated 23-8% III concentration. The cyclolactolide binary system has a min.



L31 ANSWER 54 OF 60 CAPLUS COPYRIGHT 2007 ACS ON STN

AN 1950:30074 CAPLUS Full-text

DN 44:30074

OREF 44:58471,5848a-b

TI Terpenes. VIII. The constitution of carotol. 3. A new synthesis of

1,7-dimethyl-4-isopropyl-naphthalene

AU Sorm, F.; Mleziva, J.

SO Collection of Czechoslovak Chemical Communications (1949), 14, 98-107

CODEN: CCCCAK; ISSN: 0010-0765

DT Journal

LA English

AB Carvone subjected to the Reformatskii reaction and followed by hydrolysis yielded carvacrylideneacetic acid, m. 112°, which, after boiling 6 hrs. with 100% HCO₂H, rearranged to carvacrylacetic acid, m. 69°, which, converted to the acid chloride and treated with CdMe₂, gave (2-p-cymyl)acetone, (I) b. 128°. I with Zn and BrCH₂CO₂Et, followed by treatment with HCO₂H and alkaline hydrolysis, gave 3-(2-methyl-5-isopropylphenyl)-2-methyl-2-propene-1-carboxylic acid (II), b0.9 155-7°. During the above HCO₂H treatment 20% I and EtOAc were also obtained. 3,5-Dimethyl-8-isopropyl-3,4-dihydro-1(2H)-naphthalene (III) was obtained from the ring closure (by AlCl₃) of the acid chloride of the hydrogenated form of II. III was reduced by LiAlH₄ to the alc. which was dehydrogenated to 1,7-dimethyl-4-isopropyl-naphthalene, m. 59°. The ultraviolet spectra, picrates, and stypnates of this synthetic sample and the one isolated from carotol (cf. C.A. 42, 7283b; 43, 3808b) were identical.


IT 36534-92-3P, 2-Propanone, carvacryl-

RL: PREP (Preparation)

(preparation of)

RN 36534-92-8 CAPLUS

CN 2-Propanone, carvacryl- (7CI) (CA INDEX NAME)



L31 ANSWER 55 OF 60 CAPLUS COPYRIGHT 2007 ACS ON STN

AN 1948:2730 CAPLUS Full-text

DN 42:2730

OREF 42:602d-g

TI 1-Aryl-2-oxoalkanes

IN Tindall, John B.


PA Commercial Solvents Corp.

not carried out because of poor yields of X and XI. Preparation of 1,2,4-trimethylnaphthalene (XIII) (WITH P. DES TOMBE AND H. RAMONDT): BzMe + II → VII → 2-methyl-3-phenyl-1-butanol (XVI) → 1-bromo-2-methyl-3-phenylbutane, (XV) → 1-cyano-2-methyl-3-phenylbutane (XVI) → β-methyl-γ-phenylvaleric acid (XVII) → β-methyl-γ-phenylvaleryl chloride (XVIII) → 1,2-dimethyl-4-keto-1,2,3,4-tetrahydronaphthalene (XIX) → 1,2,4-trimethyl-1,2-dihydronaphthalene (XX) → XIII. VII (C. A. 8, 1113) is reduced by the Bouveault reaction (Na in absolute EtOH) to XIV, b.p. 123-4°. XIV reacts with HBr-AcOH to give XV, b.p. 122°. XV + KCN in aqueous EtOH → XVI, which is saponified directly to XVII, b.p. 172°. XVIII, b.p. 132-3°, under the action of AlCl₃ closes the ring to give XIX, b.p. 141°, which when treated with MeMgI goes directly to XX, b.p. 109°. XX heated with its own weight of Se for 30 hrs. at 320° is dehydrogenated to XIII, which, after 2 distns. over Na, b.p. 146°, recrystd. from MeOH (platelets), m. 50°. Preparation of 1,2,6-trimethylnaphthalene (XXI) (WITH J. CUENAT AND S. BIASUTTI): p-MeC₆H₄COMe: MeCO₂Et → 2-methyl-3-(p-tolyl)-1-butanol (XXII) → 1-bromo-2-methyl-3-(p-tolyl)butane (XXIII) → 1-cyano-2-methyl-3-(p-tolyl)butane (XXIV) → β-methyl-γ-(p-tolyl)valeric acid, p-MeC₆H₄CHMeCH₂CO₂H (XXV) → methyl β-(p-tolyl)valeryl chloride (XXVI) → 1,2,6-trimethyl-4-keto-1,2,3,4-tetrahydronaphthalene (XXVII) → 1,2,6-trimethyl-4-hydroxy-1,2,3,4-tetrahydronaphthalene (XXVIII) → XXI. XXII, b.p. 132-6° (prepared by the Bouveault reaction), reacts with HBr-AcOH to give XXIII, b.p. 138-40°. XXIV is saponified to XXV, b.p. 188°, by heating in an autoclave at 150°. Ring closure of XXV, b.p. 144°, using AlCl₃ in CS₂, gives XXVII, b.p. 153°, which is reduced to XXVIII, b.p. 132-4°, by Na in EtOH. Dehydrogenation of XXVIII with Se yields XXI, b.p. 146°. Preparation of 1,2,7-trimethylnaphthalene (XXIX), apocatalene (XXX) (with Ad. Renold): p-MeC₆H₄CH₂CO₂Et (XXXI) → β-(p-tolyl)-ethanol (XXXII) → β-(p-tolyl)ethyl bromide (XXXIII) → (NaMeC(CO₂Et)₂) (XXXIV) → di-Et β-(p-tolyl)ethylmethylmalonate (XXXV) → α-methyl-γ-(p-tolyl)-butyric acid, p-MeC₆H₄(CH₂)₂CHMeCO₂H (XXXVI) → α-methyl-γ-(p-tolyl)butyryl chloride (XXXVII) → 2,7-dimethyl-1-keto-1,2,3,4-tetrahydronaphthalene (XXXVIII) → 1,2,7-trimethyl-3,4-dihydronaphthalene (XXXIX) → XXIX. XXXII, b.p. 117-8°, prepared by the reduction of XXXI with Na in absolute EtOH, when heated with 3 times its weight 33% HBr-AcOH for 24 hrs. at 100° → XXXIII, b.p. 116°. XXXIII (52 g.) and the XXXIV from 64 g. MeC(CO₂Et)₂ are boiled under reflux in C₆H₆, yield 66 g. XXXV, b.p. 191-3°. Saponification and decarboxylation of XXXV gives XXXVI, b.p. 172°, b.p. 188°, m. 50°, platelets from AcOEt. XXXVI (40 g.) and 50 g. SOCl₂ are heated until the evolution of gases ceases and then distilled directly in vacuo; yield 40.7 g. XXXVII, b.p. 142°. XXXVII (35.7 g.) and 50 g. AlCl₃ are heated in CS₂ as long as HCl is evolved, giving 27.6 g. (92.5% yield) of XXXVIII, b.p. 142°, b.p. 159°. The semicarbazone of XXXVIII m. 218°. XXXVIII is heated 4 hrs. with an excess (2 mols.) of MeMgI. After several distns. of the reaction product over 1, with a final distillation over Na, XXXIX is obtained, b.p. 130°. XXXIX is heated with twice its weight of Se 48 hrs. at 285° to dehydrogenate to XXIX, which is extracted with Et₂O and distilled over Na twice, b.p. 143°. The m. p. of mixts. of the picrates of XXIX and XXX, and of the styphnates of XXIX and XXX show that XXIX and XXX are identical. Preparation of 1,2,8-trimethylnaphthalene (XL) (with J. Hartnagel and W. Hausschild): o-MeC₆H₄COCl (XLI) → o-MeC₆H₄COMe (XLII) → (Li) o-MeC₆H₄COMe (OH)CHMeCO₂Et (XLIII) → Et (o-methyl)-α,β-dimethylcinnamate (XLIV) → 2-methyl-3-(o-tolyl)-1-butanol (XLV) → 1-bromo-2-methyl-3-(o-tolyl)butane (XLVI) → 1-cyano-2-methyl-3-(o-tolyl)butane (XLVII) → β-methyl-γ-(o-tolyl)valeric acid, (XLVIII) → β-methyl-γ-(o-tolyl)valeryl chloride (XLIX) → 1,2,8-trimethyl-4-keto-1,2,3,4-tetrahydronaphthalene (L) → XL. XLI + MeZnI → XLII, b.p. 86-9°, yield 75%. A solution of 19 g. XLI and 30 g. II in a little Et₂O is added dropwise to 14 g. I-activated Zn turnings in absolute Et₂O. The


solution is warmed to start the reaction and kept boiling vigorously for 5 hrs. The reaction product is cooled, poured into ice and HCl extracted with Et₂O, washed, dried and distilled in vacuo. Some unchanged XLII comes over first, then a mixture of XLIII and XLIV, b.p. 122-42°, which is dissolved in C₆H₆ and kept in contact with PBr₃ 24 hrs., washed with ice H₂O and NaOH, and finally heated 1 hr. with PBr₃ to split off HBr. XLIV, b.p. 128-32° (40 g.), is dissolved in a little absolute EtOH and added to 150g. Na. The mixture is warmed on the oil bath to 110-5° and just enough absolute EtOH added to permit solution of the Na. After 4 hrs. the alcoholate is decomposed with a little H₂O and heated 30 min. to saponification unchanged XLIV. The EtOH is removed with steam and the residue extracted with Et₂O. The Et₂O is washed and distilled off, leaving XLV, b.p. 141-4°. Acidification of the wash water gives 15 g. α-methyl-γ-(o-tolyl)butyric acid, b.p. 170-6°, m. (recrystd. from MePh) 111°. XLV (14.4 g.) and 100 g. 33% HBr-AcOH (5 mols.) are heated 24 hrs. in a bomb at 100°. The liquid, which is clear at first and finally seps. into 2 layers, is poured into H₂O and extracted with Et₂O. The extract is washed with H₂O and Na₂CO₃, dried and distilled; yield 17.5 g. XLVI, b.p. 134-40°. XLVI (17.4 g.), EtOH (360 g.) and 15 g. KCN (3 mols.) in 60 g. H₂O are heated 16 hrs. on the water bath. After removing most of the EtOH, XLVII is extracted with Et₂O. The crude XLVII is saponified directly by heating with 40 g. KOH dissolved in a min. of H₂O and 200 g. MeOH in the autoclave 10 hrs. at 150°. The solution is acidified and XLVIII extracted with Et₂O; yield 10 g., b.p. 183-4°, b.p. 140.5-1°. Ten g. XLVIII and 15 g. SOCl₂ are heated on the water bath. At the end of the reaction the excess SOCl₂ is removed and the XLIX distilled, b.p. 149°, yield 10.7 g. Fifteen g. powdered AlCl₃ covered with freshly distilled CS₂ is slowly mixed with 10.7 g. XLIX in the same weight CS₂ and heated on the water bath until the evolution of HCl ceases. L is recovered as in the foregoing preps., yield 8.3 g., b.p. 162-6°. The semicarbazone of L m. 225-7° (decomposition), recrystd. from EtOH. L (3.25 g.) is reduced with Na and absolute EtOH to 2.8 g. of an oil, b.p. 140-56°. This is heated with 10 g. dry Se 56 hrs. at 300-30°, yield 1.9 g. XL, b.p. 150° (approx.). Preparation of 1,3,7-trimethylnaphthalene (LXI) (with P. Pieth and R. Thomann): p-tolualdehyde + II in the presence of Zn in C₆H₆ → Et β-(p-tolyl)-β-hydroxy-α-methylpropionate (LXII), b.p. 159-60°, b.p. 168°, 90% yield. LXII → Et β-methyl-α-methylcinnamate (LXIII) → 3-(p-tolyl)-2-methylpropanol (b.p. 129°) → γ-(p-tolyl)-β-methylpropyl bromide (b.p. 125°) → γ-(p-tolyl)-β-methylbutyryl chloride → γ-(p-tolyl)-β-methylbutyric acid (b.p. 167-71°) → γ-(p-tolyl)-β-methylbutyryl chloride (LXIV), b.p. 131-2° → 3,7-dimethyl-1-keto-1,2,3,4-tetrahydronaphthalene (LXV) → 1,3,7-trimethyl-3,4-dihydronaphthalene (LXVI) → LXI, b.p. 131-3°, d₄21.9801, n_D20 1.5972. After bromination of LXII with PBr₃, HBr is split off with PhNMe₂ to give LXIII, b.p. 149°. LXIV → LXV, b.p. 139°, m. 47°, when treated with AlCl₃ in CS₂, yield 90%. The semicarbazone of LXV, recrystd. (platelets) from MeOH, m. 204° (decomposition). The reaction product of LXV + MeMgI distilled over 1 and then distilled over Na → LXVI, b.p. 115-7°. LXVI heated 33 hrs. with its own weight of Se at 300-30° → LXI, which is purified by distillation over Na. Preparation of 1,4,5-trimethylnaphthalene (LXVII) (with E. Hefci and A. Ramon Altuna): p-xylol Me ketone (Ber. 18, 1856(1895)) + II → Et 2,5-dimethyl-β-methylcinnamate, b.p. 148-50° → 3-(2,5-dimethylphenyl)-1-butanol, b.p. 141° → 1-bromo-3-(2,5-dimethylphenyl)butane, b.p. 134-5° → γ-(2,5-dimethylphenyl)valeronitrile → γ-(2,5-dimethylphenyl)valeric acid, b.p. 170°. m. 113.5° → γ-(2,5-dimethylphenyl)valeryl chloride, b.p. 144-5° → 1,4,5-trimethyl-8-keto-5,6,7,8-tetrahydronaphthalene, b.p. 138°, which is reduced with Na in absolute EtOH to 1,4,5-trimethyl-8-hydroxy-5,6,7,8-tetrahydronaphthalene, b.p. 128° → LXVII, b.p. 145°, m. 63° (recrystd. from MeOH). The procedures are the same as those for LXI. Preparation of 1,4,6-trimethylnaphthalene (LXVIII) (with W. H. Addink): p-MeC₆H₄COMe + II → Et p-

methyl-β-methylcinnamate, b.p. 158-60° → 3-(p-tolyl)-1-butanol, b.p. 150° → 1-bromo-3-(p-tolyl)butane, b.p. 140° → γ-(p-tolyl)valeronitrile → γ-(p-tolyl)valeric acid, b.p. 155° → γ-(p-tolyl)valeryl chloride, b.p. 145-7° → 1,6-dimethyl-4-keto-1,2,3,4-tetrahydronaphthalene, b.p. 157-60° → 1,4,6-trimethyl-1,2-dihydronaphthalene, b.p. 135-8° → LXVIII, b.p. 140-2°. Preparation of 2,3,5-trimethylnaphthalene (LXIX) (with A. Meisner): Equal parts of o-MeC₆H₄CH₂COCl and MePh are allowed to react into MeZnI in ice-cooled Et₂O. At the end of the reaction ice water is added, o-tolylacetone (LXX) recovered and distilled, b.p. 122°, yield 60%. LXX + II with Zn in C₆H₆ → a mixture, b.p. 130-70°, of unacid and HO acids which is treated with PBr₃ and PhNMe₂ to give Et α,β-dimethyl-γ-(o-tolyl)crotonate, o-MeC₆H₄CH₃COMe: MeCO₂Et, b.p. 130-45°, which is reduced (Pt catalyst) at 80° to Et α,β-dimethyl-γ-(o-tolyl)butyrate (LXXI), b.p. 143-8°. LXXI is saponified to the acid (LXXII), b.p. 177°, with KOH-EtOH. LXXII → Et α,β-dimethyl-γ-(o-tolyl)butyryl chloride, b.p. 144-6° → 2,3,5-trimethyl-1-keto-1,2,3,4-tetrahydronaphthalene, b.p. 148°, which is reduced with Na in EtOH to 2,3,5-trimethyl-1-hydroxy-1,2,3,4-tetrahydronaphthalene (LXXIII), b.p. 142°, approx. LXXIII is dehydrogenated by heating with Se to give LXIX which, purified by distillation over Na, N₂ 138°. Preparation of 2,3,6-trimethylnaphthalene (LXXIV) (with A. H. Rierink): NaOEt (34 g.) is added to a mixture of 90 g. II and 60 g. p-tolualdehyde during 3 hrs. The mixture (cooled with ice-NaCl during the addition and overnight) is allowed to stand 2 hrs. at room temperature and finally heated 6 hrs. on the water bath. The product is decomposed with ice water, acidified with dilute AcOH and extracted with Et₂O. The Et₂O solution is washed and dried, the Et₂O removed and Et α-methyl-β-(p-tolyl)-α,β-oxidoisopropionate (LXXV) distilled over, b.p. 148-52°, yield 62.5 g. LXXV is saponified by heating 3 hrs. with 7 g. Na in 150 cc. EtOH. The product is diluted with H₂O and the EtOH removed with steam. After acidification α-methyl-β-(p-tolyl)-α,β-oxidoisopropionic acid (LXXVI) is taken up in Et₂O, washed and dried. The Et₂O is removed and LXXVI is decarboxylated by heating 24 hrs. at 180° to give p-tolylacetone (LXXVII), b.p. 109-10°, yield 41.8 g. LXXVII, II and Zn turnings in C₆H₆ → a mixture of HO and unsatd. acids, b.p. 150-70°, which is completely dehydrated by treatment with PBr₃ and PhNMe₂ to give Et α,β-dimethyl-γ-(p-tolyl)crotonate (LXXVIII), b.p. 158-63°. LXXVIII in AcOEt is reduced catalytically (Pt) to Et α,β-dimethyl-γ-(p-tolyl)butyrate, b.p. 148-51°, which is saponified to the acid (LXXIX), b.p. 148-50°. LXXIX → α,β-dimethyl-γ-(p-tolyl)butyryl chloride, b.p. 140° → 2,3,6-trimethyl-4-keto-1,2,3,4-tetrahydronaphthalene, b.p. 152-4° → 2,3,6-trimethyl-4-hydroxy-1,2,3,4-tetrahydronaphthalene, b.p. 146-8°. An incomplete preparation of LXXIV (with R. Delbes): LXIII in AcOEt is reduced (Pt) to Et α-methyl-β-(p-tolyl)propionate, b.p. 130-32°, which is saponified to the acid, b.p. 168-9° → α-methyl-β-(p-tolyl)propionyl chloride (LXXX), b.p. 144-7°. LXXX heated with MeZnI in Et₂O → 1-(p-tolyl)-2-methylbutan-3-one, b.p. 124-7°, which is reduced with Na in abs. EtOH to 1,2-dimethyl-3-(p-tolyl)-1-propanol (LXXXI), b.p. 135-7°. LXXXI is heated at 100° with 30% HBr-AcOH. Upon distillation of the reaction product a poor yield (10%) of the expected bromide was obtained and it was concluded that LXXXI had been dehydrated. The synthesis was discontinued at this point.

IT 2096-86-8P, 2-Propanone, 1-(p-tolyl)-51052-00-7P,
2-Propanone, 1-(o-tolyl)-
RL: PREP (Preparation)
(preparation of)
RN 2096-86-8 CAPLUS
CN 2-Propanone, 1-(4-methylphenyl)- (CA INDEX NAME)



RN 51052-00-7 CAPLUS
CN 2-Propanone, 1-(2-methylphenyl)- (CA INDEX NAME)




L31 A MSHER 60 OF 60 CAPLUS COPYRIGHT 2007 ACS ON STN
AN 07012321 CAPLUS Full-text
DN 12321


ORF 1:3005e-1,3006a-1,3007a-b
TI Benzene Hydrocarbons With a Pseudo-Allyl Side Chain: Methovinyl Benzene and Its Homologues. Study of Certain Molecular Migrations
AU Tiffeneau, M.
SO Ann. chim. phys., [8] (1907), 10, 145-98
DT Journal
LA Unavailable
GI For diagrams, see printed CA Issue.
OT The benzene hydrocarbons with a pseudo-allyl side chain may be made in general by the dehydration of the corresponding carbinol. They show the characteristic reactions of unsaturated hydrocarbons, giving dihalides and halohydrins. The iodohydrins undergo a curious transformation when their ethereal solutions are treated with an excess of aqueous AgNO₃, in that a ketone is formed; thus the iodohydrin of methovinylbenzene, C₆H₅CH₃CH(OH)CH₂I, gives phenyl acetone, C₆H₅CH₂COCH₃, according to the equation C₆H₅CH₃CH(OH)CH₂I + H₂O + C₆H₅CH₂COCH₃. With aqueous KOH the chlor- and iodohydrins give oxides, thus C₆H₅CH₃CH(OH)CH₂I + C₆H₅CH₂COCH₃. Methovinylbenzene was obtained most satisfactorily by the dehydration of dimethylphenylcarbinol. The latter compound may best be made by the action of methylmagnesium iodide on methylbenzoate (Grignard, Ann. univers. Lyon, nouv. serie, 8, 73, (1901)), or by the action of acetone on phenylmagnesium bromide (Tissier and Grignard, Compt. rend., 132, 1182). The dimethylphenylcarbinol is purified by dissolving it in its volume of petroleum ether, cooling the solution and shaking continually until the carbinol separates in crystalline form. The dehydration of the carbinol to form the methovinyl benzene may be accomplished in a variety of ways: by slow distillation; by heat in the presence of a catalyst, viz., Al₂O₃ or reduced Cu; by anhydrous oxalic acid. Methovinylbenzene may also be obtained by decomposing the product of the reaction of methylmagnesium iodide on acetophenone, or better, on ethyl or methyl benzoate. Alkalies decompose dimethylphenylchloromethane with the formation of methovinylbenzene. Methovinylbenzene b. 161-162°. (See also Grignard, Ann. univers. Lyon, nouv. serie, 100 (1901); Klages, Ber., 35, 2640 and 3507; Matsubara and Perkin, Jr., J. Chemical Society, 87, 668). By the action of H₂SO₄ on

methovinylbenzene a dimeride (See Grignard, Ann. Universita Lyon, 102, (1901), m. 51-52, b14-15 163-164* is formed, or when a slight excess of methyl iodide (only 1/2 mol. CH_2MgI) is used a polymeride is also obtained, b10 175*, DO-1.012. (See Klages, Ber., 35, 2640). Methovinylbenzene is reduced to cumene by Na and absolute alcohol (Tiffeneau, Compt. rend., 134, 845), which furnishes a general method for the preparation of aromatic compounds having an isopropyl side chain. By passing it over reduced Ni, either cumene or hexahydrocumene is obtained, according to the activity of the Ni and length of time occupied in the process. Oxidation by air or KMnO_4 gives acetophenone. α -Methylstyrolene dichloride, $\text{C}_6\text{H}_5\text{CClCH}_2\text{CH}_2\text{Cl}$, is formed by action of Cl on methovinylbenzene, b15 119-121*, d0 1.2172. By heating with alcoholic KOH it gives β -chloro- α -methylstyrolene, $\text{C}_6\text{H}_5\text{CCH}_3\text{CHCl}$, b. 210-215*, b14 102-106*. α -Methylstyrolene dibromide, $\text{C}_6\text{H}_5\text{CBrCH}_2\text{CH}_2\text{Br}$ (Grignard, Matsubara and Perkin, Jr.), was made from methovinylbenzene and Br in ether, petroleum ether or CS_2 , b2 115-125*. ω -Bromoethylstyrolene, $\text{C}_6\text{H}_5\text{C}(\text{CH}_3)\text{CH}_2\text{Br}$, is formed by the action of alcoholic KOH on the dibromide of methovinylbenzene or by Na_2CO_3 on methylcinnamic acid; b2 105-106*, b. 225-228* without decomposition, d0 1.366. Oxidation with KMnO_4 in the cold gave acetophenone, which was characterized by its semicarbazone. This shows that the formula is $\text{C}_6\text{H}_5\text{CCH}_3\text{CH}_2\text{Br}$, rather than $\text{C}_6\text{H}_5\text{CCH}_2\text{CH}_2\text{Br}$, since the latter would give bromoacetophenone. Heated with KOH it gives phenylallylene. $\text{C}_6\text{H}_5\text{C}\cdot\text{C}\cdot\text{CH}_2\text{CH}_2\text{C}\cdot\text{C}_6\text{H}_5$. With phenyl Mg bromide it gives methylstilbene. ω -Bromoethylstyrolene acts on metallic Mg in the presence of dry ether, and the product thus obtained on treatment with water gives a number of substances, viz., methovinylbenzene, phenylpropylene, phenylallylene and diphenyl-2,5-hexadiene-2,4, $\text{C}_6\text{H}_5\text{CH}_3\text{C}=\text{CH}\cdot\text{CH}=\text{CCH}_3\text{C}_6\text{H}_5$. (See Tiffeneau, Bulletin society chim., [3] 26, 1186; Compt. rend., 135, 1346). By passing dry CO_2 through the mixture obtained by action of Mg in dry ether, an addition product is obtained which on acidification gives two acids, one m. 97-98* and the other at 130*, which are probably the two stereoisomeric β -methylcinnamic acids. The acid which m. 97-98* has been obtained also by the dehydration and saponification of the product of the condensation of acetophenone with ethyl iodacetate in the presence of Zn or Mg (Tiffeneau, Compt. rend., 138, 985). Treated with HI it gives dihydromethylcinnamic acid and at the same time cumene is formed by the loss of CO_2 . Addition of hypochlorous acid gives a small quantity of methylphenylchloroacetic acid and methylchlorostyrolene. Chlorhydrin of methylphenylglycol, $\text{C}_6\text{H}_5\text{CH}_2\text{CH}_2\text{COH}\cdot\text{CH}_2\text{CH}_2\text{Cl}$, b19 124-125*, d0 1.168. With dimethylamine it gives the dimethylamino derivative; (Fourneau, Compt. rend., 138, 736) with diethylamine, diethylaminophenyl-2-propanol-2, $\text{C}_6\text{H}_5\text{CH}_2\text{COHCH}_2\text{N}(\text{C}_2\text{H}_5)_2$, b23 138-140*. The cinnamyl derivative m. 190-192*. Bromhydrin of methylphenylglycol, $\text{C}_6\text{H}_5\text{CH}_2\text{CH}_2\text{COHCH}_2\text{CH}_2\text{Br}$, b10 141*, d 1.413. Iodohydrin, b12 144-145*, d 1.541. It gives the same amino alcohol with methylamine as that given by the chlorhydrin, establishing its analogous constitution. These chlor- and iodohydrins on heating with aqueous KOH give the oxide of methovinylbenzene $\text{C}_6\text{H}_5\text{CCH}_3\text{CH}_2$, b16 84-85*, d0 1.043. This is easily isomerized into hydratropic aldehyde. The iodohydrin in ethereal solution when agitated with concentrate AgNO_3 solution in excess, loses HI, and undergoes a curious transformation into phenylacetone. It was found that substitution in the benzene ring did not affect the nature of the transformation. α -Methovinyltoluene, $\text{CH}_3\text{C}_6\text{H}_4\text{C}(\text{Me})=\text{CH}_2$, b. 168-169*, was made by dehydrating dimethyl- α -tolyl carbinol, m. 41*, which can be obtained either by the action of acetone on the Mg compound of α -bromotoluene or methyl-Mg iodide on methyl α -toluate. Distillation with oxalic acid gives α - β -allyltoluene, b. 168-169*, d0 0.0076, which on oxidation with KMnO_4 yields α -tolylmethylketone, b. 216*. The iodohydrin with AgNO_3 gives by molecular transposition, α -tolylacetone, b. 227*, oxime, m. 75*, semicarbazone, m. 181*. α -Methovinyltoluene, b. 183-185*, d0 0.9115. The iodohydrin gives with AgNO_3 α -tolyl acetone, b. 228-229*. Semicarbazide, m. 139*. α -Methovinyltoluene, b. 184-185*, d 0.9122, (Errera, Gazz. chim. ital., 31, 88 gives b. 198-200*) has odor of thyme. Dibromide does


not crystallize at -15*. Heated with water and BaCO_2 , it gives the glycol, m. 32*. With H_2SO_4 it gives a dimeride, m. 40*. The iodohydrin is transformed into α -tolylacetone, b. 232-233*, giving oxime, m. 90*, and semicarbazone, m. 158*. Dimethylamine converts the iodohydrin into the corresponding α -tolylmethylidimethylaminoethylcarbinol, b. 253*-255*, d0 0.982. IT 2096-86-8, 2-Propanone, 1- α -tolyl- 51052-00-7, 2-Propanone, 1- α -tolyl- (and derivs.) RN 2096-86-8 CAPLUS CN 2-Propanone, 1-(4-methylphenyl)- (CA INDEX NAME)



RN 51052-00-7 CAPLUS
CN 2-Propanone, 1-(2-methylphenyl)- (CA INDEX NAME)



IT 18826-61-4P, 2-Propanone, 1-m-tolyl-
RL: PREP (Preparation)
(preparation of)
RN 18826-61-4 CAPLUS
CN 2-Propanone, 1-(3-methylphenyl)- (CA INDEX NAME)



-- log hold
'HOLD' IS NOT VALID HERE
For an explanation, enter "HELP LOGOFF".

-- log hold
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	ENTRY	TOTAL	SESSION
329.67		1152.09	

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	-46.80	-46.80

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 15:48:11 ON 03 NOV 2007